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COMPARISON OF INTRAMUSCULAR 
DEXMEDETOMIDINE AND INTRAMUSCULAR 
MIDAZOLAM IN LAPAROSCOPIC INTRA ABDOMINAL 
SURGERIES. 
INTRODUCTION 
 
 Surgery and anaesthesia cause significant fear and anxiety in patients. It 
causes sympathetic nervous system stimulation that leads to adverse 
cardiovascular effects like tachycardia and hypertension.Preoperative anxiety is 
a challenging concept in the preoperative care of patients and almost all patients 
undergoing surgery experience varying level of anxiety.  
 
The incidence of preoperative anxiety is 60–80% of surgical patients. 
Drugs like phenothiazine, barbiturates, opioids and benzodiazepines are used to 
relieve anxiety preoperatively29 
 
Premedication is administration of anaesthetic adjuvant drugs to allay 
anxiety, decrease post-operative pain, nausea and vomiting and the risk of 
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pulmonary aspiration.Clinically used routes of administration of premedication 
are oral, rectal, intramuscular, intravenous and intranasal.  
Midazolam, a benzodiazepine is the drug of choice as premedicant to 
decrease anxiety. Other classes of drugs used for anxiolysis and sedation are 
barbiturates and α-2-agonists.1 
 
After the discovery of alpha agonists, its usefulness in anaesthesia like 
anaesthetic adjuvant for general anaesthesia and regional anaesthesia, 
intravenous sedation for short procedures, intravenous sedation in ICU and as 
an additive to neuraxial and peripheral nerve blocks are investigated. 
 
 There are number of reasons for therenewed interest in the use of 
dexmedektomidine, a newer alpha2 agonist, as sedative premedication. 
Dexmedetomidine, when compared to clonidine is a more selective alpha2-
adrenoceptor agonist, which allows its use in relatively high doses for sedation 
and analgesia without the unwanted vascular effect from activation of alpha1-
receptors. Dexmedetomidine is shorter acting than clonidine. These properties 
make dexmedetomidine suitable for premedication and as an anaesthetic adjunct 
for general and regional anaesthesia. 
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There has been a constant search for an agent that effectively suppresses 
all hazardous response to obnoxious stimuli with good safety margin. 
Dexmedetomidine has most of the characteristics of premedication (like 
sedation, anxiolysis, analgesic sparing effect, sympathetic blockade, dryness of 
mouth). Hence we decided to study the effectiveness of dexmedetomidine as a 
pre medication agent. 
 
AIM OF THE STUDY 
 
The aim of our study is to compare sedation and anxiolysis in two groups 
receiving intramuscular dexmedetomidine 1.0mic/kg and intramuscular 
midazolam 0.05mg/kg for laparoscopic abdominal surgeries given 60 minutes 
before surgery. 
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PREMEDICATION 
 
Premedicationis the administration of medication before anaesthesia. 
Premedication is used to prepare the patient for anaesthesia and to provide 
optimal conditions for surgery. “Premedication   places the patient in a tranquil 
frame of mind. That is  the principal  reason, not  on  humane grounds  only,  
although  the  worst  part  of  an operation from  the patient’s  point  of  view  is 
often the  few hours  preceding it, but  on physiological  grounds,  because  a  
patient  in  a  tranquil  frame of  mind requires  less  anesthetic than  one  who  
is  apprehensive, and  consequently  he  makes  a  better recovery” said De caux 
about premedication. 
 
History of premedication: 
 
In the past, Opioid analgesics were used as premedication, as it has good 
sedative and analgesic effects. Opioids enhance the effects of other 
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anaestheticagents. For this quality, opioids were preferred premedication, when 
no potent inhalational agents were available. 
 
 But there were certain disadvantages with opioid premedication. They 
caused euphoria when given to patients who did not have any pain and caused 
delay in gastric emptying and PONV. In addition, augmentation of CNS 
depressant effect of other anaesthetic agents was undesirable.  
 
Till 1960, the preferred combination was IM opioids like meperidine or 
morphine given along with atropine 30-45 minutes before surgery. “Twilight 
sleep” a sedation caused by hyoscine and papaveretum was preferred by some 
anesthesiologist.2 
 
Rectal administration of powerful CNS agents like paraldehyde or 
thiopentone was used forpre-anaesthetic sedation in the preoperative period 
especially in uncooperative paediatric patients. 
 
 Apart from rectal barbiturates, oral barbiturates were also tried in the 
past for inducing hypnosis in preoperative period. But all these agents are not 
preferred after the advent of potent inhalational agents, short acting opioids and 
short acting muscle relaxants. 
Now a day, benzodiazepines are the preferred agents. 
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PREOPERATIVE ANXIETY: 
 
It is a state of psychological stress which results in low level of 
hypothalamic-pituitary axis activation and cytokine release. Salivary cortisol 
levels increases by 50% after the patients come to know about the surgery. Beta 
endorphin and epinephrine concentration goes up preoperatively. There is no 
proven additive effect of this preoperative stressor response with the 
intraoperative stress due to surgery. 
 
 Young patients, patients who have not had any previous anesthetics, 
patients with previous negative experience with anesthesia and female patients 
usually have higher anxiety scores. 
 
MEASURING LEVELS OF PREOPERATIVE ANXIETY: 
Visual analog scale: 
 This scale was first described by Bond MR and Pilousky in 1966 
for measuring pain intensity. It uses 10 cm visual scale, one end of which shows 
7 
 
no pain and the other end showing worst possible pain. The same scale can be 
used to assess anxiety, where 0 indicates no anxiety and 10 indicates extreme 
anxiety.   
 
 
 
 
Spiel Berger state anxiety inventory (STAI): 
 
The spiel Berger state anxiety inventory (STAI) has 20 self-reported 
statements that investigate how a patient feels at a particular time.  
STAI is rated on a four-point scale for the patient’s agreement with any 
statement (not at all, somewhat, moderately so, and very much so).The total 
score for STAI ranges from 20 to a maximum of 80.  Low anxiety score is 20–
37, moderate anxiety score is 38–44 and high anxiety is 45–80. 
Observer’s anxiety criteria: The patient’s anxiety is assessed by an 
observer who is not involved in the study. They are graded as follows. 
Grade 1: Calm 
Grade 2: Mild anxiety 
Grade 3: Moderately anxious 
Grade 4: Extremely anxious 
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 Other scoring systems to asses anxiety are beck anxiety inventory, 
Hamilton anxiety rating. 
 
 
 
MEASURING LEVELS OF PREOPERATIVE SEDATION: 
 
Subjective sedation scale21 
1. Fully awake and conscious 
2. Awakens on verbal commands 
3. Awakens on gentle shaking 
4. Awakens on vigorous shaking and painful stimuli 
5. Unarousable 
 
 Ramsay sedation scores 
 
1. Agitated, restless 
2. Cooperative, tranquil 
3. Responds to verbal commands while sleeping 
4. Brisk response to glabellar tap or loud voice while sleeping 
5. Sluggish response to glabellar tap or loud voice 
6. No response to glabellar tap or loud voice 
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PHARMACOLOGY 
 
MIDAZOLAM 
Fryer and Walser's in 1976 first synthesized midazolam, the first 
clinically used water-soluble benzodiazepine3. Midazolam is a water-soluble 
benzodiazepine that is available in an acidified (pH 3.5) aqueous formulation 
that produces minimal local irritation after IV or intramuscular (IM) injection. 
At physiologic pH, an intramolecular rearrangement occurs that changes the 
physicochemical properties of midazolam such that it becomes more lipids 
soluble. 
 
All benzodiazepines have anxiolytic, amnestic, sedative, hypnotic, 
anticonvulsant, and spinally mediated muscle relaxant properties. The dose-
dependent pharmacologic activity implies that the CNS effects of various 
benzodiazepine compounds depend on the affinity for receptor subtypes and 
their degree of receptor binding. Although benzodiazepines can be used as 
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Mechanism of Action: 
 
GABA is the principal inhibitory neurotransmitter within the CNS. 
Benzodiazepines facilitate the inhibitory neurotransmission by GABA. After 
binding to GABA receptors, BZDs induces allosteric modification in GABA 
receptors and increases the chloride conductance.  This leads to 
hyperpolarization of CNS and CNS becomes resistant to excitation7.  
 
 
 
 
 
 
Schematic diagram of GABAA Receptor 
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STRUCTURE OF GABA A RECEPTOR: 
GABA A receptor is a pentameric structure containing two alphas, two 
beta and a gamma glycoprotein subunits. The binding of BZD to receptor site 
increases the efficiency of coupling between the GABA receptor and the 
chloride channel. 
 
The degree of allosteric modulation caused by BZD is limited and this 
explains the   “ceiling effect” of CNS depression by BZD.6  
Alpha 1 receptor binding is responsible for sedation, amnesia and its 
anticonvulsant properties, whereas alpha 2 receptor binding is responsible for 
muscle relaxation and anxiolysis. 
The concentration dependent receptor occupancy of BZD is responsible 
for various drug effects. Anxiolysis is produced by 20% receptor occupancy. 
Amnesia and sedation are produced at 30-50% receptor occupancy. Hypnosis 
and unconsciousness needs 60% of receptor occupancy6, 20, 
 
Mechanism of anxiolysis: 
 
The exact mechanism is not known. Midazolam premedication reduces 
intraoperative epinephrine, norepinephrine and cortisol release. It is observed 
that midazolam did not suppress cortisol release in response to exogenous 
13 
 
ACTH. This suggests that benzodiazepines act at a higher level of   like 
hypothalamus or pituitary. 
Benzodiazepines when given in combination with opioids are more 
effective in blunting the rise in serum catecholamine, cortisol, arginine 
vasopressin and ACTH rather than benzodiazepines alone3. 
 
 
Commercial Preparation & Dosage 
 
The preservative in injection Midazolam solution is 0.8% sodium 
chloride, 0.01% disodium edetate, and 1% benzyl alcohol the pH is adjusted to 
3 with hydrochloric acid. As midazolam is lipid soluble drug and has pH-
dependent solubility, it is water soluble as formulated in a buffered acidic 
medium. 
 
 Stability of midazolam   in solution and rapid metabolism is due to the 
imidazole ring. The rapid CNS effect and large volumes of distribution is due to 
high lipophilicity3. Midazolam 0.04 to 0.08mg/Kg IV/IM is the most common 
dosage used for premedication.5,6 .oral and midazolam is given at dose of 0.5 
mg/kg. Buccal midazolam is available as 5 mg/ml prefilled syringes with 2.5, 5, 
7.5 and 10 mg. Preparation for parenteral use is available as 1mg/ml and 
5mg/ml solutions. 
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Metabolism: 
Benzodiazepines undergo hepatic metabolism via oxidation and 
glucuronide conjugation. Oxidation reactions are susceptible to hepatic 
dysfunction and co administration of other anesthetic drugs.Midazolam 
undergoes oxidation by hepatic enzymes to form hydroxylated metabolite, 
which is water soluble and excreted in the urine. 
 
  The primary metabolite, 1-hydroxymethylmidazolam, is a mild CNS-
depressant. The hepatic clearance rate of midazolam is five times greater than 
lorazepam and 10 times greater than diazepam.  Reduction in hepatic blood 
flow and age can affect the midazolam’s clearance. 
 
 CARDIOVASCULAR EFFECTS: 
 
Midazolam produces decrease in systemic vascular resistance and blood 
pressure when large doses are administered for induction of anaesthesia. 
However, the cardiovascular depressant effects of benzodiazepines are 
frequently “masked” by laryngoscopy and intubation. The cardiovascular 
depressant effects are directly related to the plasma concentration. However, a 
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plateau plasma concentration appears to exist, above which the changes in blood 
pressure are less5. 
 
RESPIRATORY EFFECTS: 
The ventilatory response to hypoxia is depressed particularly in 
hypercarbic patients. Supplemental oxygen may be needed to prevent hypoxia, 
with continuous observation of airway patency and respiration. 
 
Minor respiratory depression is more profound in the presence of limited 
respiratory reserve and old age. Profound respiratory depression and apnea are 
seen with synergistic interaction with other opioids7.  
 
AIRWAY REFLEXES: 
 
Benzodiazepines depress the swallowing reflex and decrease the upper 
airway reflex activity by reducing the tonic and phasic contraction of airway 
muscles7. 
 
DEXMEDETOMIDINE  
 Dexmedetomidine is a selective α2-agonist, with 1600-fold greater 
selectivity for the α2-receptor. Adrenergic receptors were first differentiated into 
α and β by Ahlquist based on their responses to various amines.  α2-
16 
 
Adrenergicagonists provide sedation, anxiolysis, and hypnosis, as well as 
analgesia and sympatholysis. 
  Initially anaesthesiologists were reluctant to use α2-agonists in 
anaesthesia due to adverse events observed in patients who were receiving 
clonidine therapy. The MAC reducing property of clonidine increased the use of 
this alpha agonist in clinical practice.  Recently dexmedetomidine has been 
approved for brief sedation (<24 hours) for mechanically ventilated patients in 
ICU.  
 
Physicochemical Characteristics 
Medetomidine is a selective α2-adrenergic agonist. Dexmedetomidine is 
its specific dextro enantiomer and is available as a parenteral formulation. It is 
freely water soluble. It belongs to imidazole subclass of alpha 2 receptor 
agonists.  
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Structure of dexmedetomidine 
 
 
Commercial preparation and dose: 
 
Itis available as 100mic/ml in one or two ml ampoules. The loading dose 
for intravenous infusion is 0.5 to 1 mic/kg over 10 minutes followed by 0.2to 
0.7 mic/kg/hr. The effect starts after 5-10 minutes and lasts for 30 -60 minutes. 
 
 Metabolism and pharmacokinetics: 
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Dexmedetomidine has a rapid distribution and extensive metabolism in 
the liver. It is excreted both in urine and faeces. It undergoes glucuronide 
conjugation. Dexmedetomidine is 94% protein bound.  The elimination half-life 
is 2 to 3 hrs. 
 
 These pharmacokinetic parameters appear to be unaltered by age, weight, 
or renal failure, but clearance is a function of height. The concentration ratio 
between whole blood and plasma is 0.66.3   Time to peak plasma concentration 
after intramuscular injection is 1.6 to 2.4 hours.19 
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initial increase in BP is not seen. The heart rate and blood pressure remains 
within 10% of baseline. 
 
 
 
 
 
 
Effects on the Central Nervous System 
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Sedation: 
The α2 agonists produce their sedative-hypnotic effect by an action on α2 
receptors in the locus caeruleus .The quality of sedation produced by 
dexmedetomidine seems different compared with that produced by other 
sedatives acting through the GABA system. 
 
 The sedation caused by dexmedetomidine is associated with less 
respiratory depression. It acts through the endogenous sleep-promoting 
pathways to exert their sedative effect. It decreases the triggering between locus 
ceruleus and mediolateralpreoptic nucleus. It increases the histamine release in 
the cortical and sub cortical projections. 
 
Central Nervous System Protection and Other Central Nervous 
System Effects: 
The CNS protective effects are not well defined. It reduces the cerebral 
catecholamine outflow during injury and resulted in less neural tissue damage 
with better neurologic outcome. The neuroprotective properties of 
dexmedetomidine in humans have not been investigated. Little is known of the 
effects of dexmedetomidine alone on ICP and CBF. It reduces the muscle 
rigidity caused by high dose opioids 
 
Analgesia: 
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The analgesic effect of dexmedetomidine is due to its action on alpha 2 
receptors in locus ceruleus and spinal cord.  Narcotic sparing effect is seen after 
systemic use of dexmedetomidine. 
Effects on the Respiratory System 
 Dexmedetomidine sedation reduces minute ventilation, but the slope of 
the carbon di oxide response curve is preserved. This change is similar to 
normal sleep. There is no change in pao2 or Ph. Dexmedetomidine induces 
arousal on hypercarbia. This phenomenon is similar to normal sleep and is a 
protective mechanism. 
 
Effects on the Cardiovascular System 
The basic effects of α2 agonists on the cardiovascular system are 
decreased heart rate; decreased systemic vascular resistance; and indirectly 
decreased myocardial contractility, cardiac output, and systemic blood pressure. 
By developing highly selective α agonists, it has been hoped to decrease 
some of these adverse cardiovascular effects and to maximize the desirable 
hypnotic-analgesic properties. It has a biphasic response after intravenous bolus 
injection. 
 An initial increase in blood pressure due to peripheral alpha2 stimulation 
and later a fall in BP22.Such initial increase in BP are not seen after an IM 
injection. Itremained within 10% of baseline. 
Antagonist: 
24 
 
Atipamezole readily reverses the effects of dexmedetomidine. It is not 
currently approved for human use3. 
ENDOCRINE EFFECTS: Dexmedetomidine decreases the release of 
catecholamine and reduces the stress response to intubation and surgery. 
 
SIDE EFFECT: 
It causes dry mouth, bradycardia, hypotension, hypertension, atrial 
fibrillation, nausea.  These side effects occur mostly during the infusion of 
loading dose. 
 
Uses 
Flacke listed the potential uses of sympatholytic drugs in the future. In 
addition to the reducing effect of MAC and the absent respiratory depression, 
the following properties seem particularly valuable to the anaesthesiologist : 3 
1. They are potent analgesics. 
2. They are sedatives and anxiolytics. 
3. They are antisialogogues. 
4. They may promote hemodynamic stability. 
5. Homeostatic reflexes remain intact. 
6. They attenuate opioid rigidity (in animals). 
7. Their circulatory actions can be reversed. 
REVIEWOF LITERATURE 
25 
 
1. H. Ronald Vinik, (Anesthesia & Analgesia  1982)32 The 
authorstudied the effect of premedication with 0.07 mg/kg midazolam , 
1.0mg/kg hydroxyzine  and  placebo midazolam diluent  given intramuscularly 
in 100 ASA PS 1 and 2   patients  who underwent general surgery. 
 In the anxiety evaluation, AVAT and objective anxiety evaluation were 
done. Midazolam and hydroxyzine produced reduction of anxiety greater than 
placebo which was significant (p< 0.05).  Hemodynamic variations were 
similar in all the groups. No adverse reactions were observed before 
anesthesia. It was concluded that midazolam is an efficacious and safe 
premedication in healthy patients.  Minimal tissue irritation was observed with 
midazolam.  Onset of action of intramuscular midazolam was found to be 
prompt.  
 
2. Riku E. (Anesthesia Analgesia1990) conducted a study in 20 
healthy ASA PS 1 patients by single blind method. The effects on anesthetic 
requirements, hemodynamics and catecholamine levels in plasma using four 
different doses (0.167, 0.33, 0.67, and 1 .0 microgram/kg) of 
dexmedetomidine intravenous infusion when the subjects underwent uterine 
dilatation and curettage. 
 Conclusion was tolerance to dexmedetomidine was good and drug-
related subjective side effects or adverse events were not serious. Reductions 
in Blood pressure, heart rate and plasma norepinephrine levels were reduced 
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after dexmedetomidine administration. The optimal dose for single-dose 
intravenous premedication in minor surgery seems to be 0.334to 0.67 mic/kg.  
 
3. MarkkuAnttila (Br J ClinPharmacol. 2003) studied   
dexmedetomidine’s bioavailability in healthy subjects. 12 healthy males were 
given 2 µg/kg single dose of dexmedetomidine intravenously, intramuscularly, 
per orally and buccally. The drug concentration-time data were analyzed by 3 
methods. They are linear one-compartment (buccal and per oral data), or two-
compartment modeling (intravenous data), or noncompartmental methods 
(intramuscular data). Mean (95% CI) absolute bioavailability after per oral, 
buccal and intramuscular administration was 16% (12–20%), 82% (73–92%) 
and 104% (96–112%), respectively. 
 
4. M.L. Jaakola et al 4(Acta analgesia DEC 
2008)Dexmedetomidine as a preanaesthetic agent - Phase I-III study 
Dexmedetomidine effectively induced sedation and anxiolysis in subjective 
VAS estimates. It was administered as one single i.v bolus before intravenous 
regional anaesthesia and other as an intramuscular premedication before 
general anaesthesia. Sedation and anxiolysis produced were same as that 
produced by i.m. midazolam premedication. 
 
They have acknowledged that in the perioperative setting 
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dexmedetomidine have many desirable properties. Control of haemodynamic 
and adrenergic responses to noxious stimuli by dexmedetomidine were good. 
They concluded that dexmedetomidine alone is not sufficient to produce 
clinically adequate anaesthesia. But it will remain as a good anaesthetic 
adjuvant. 
 
5. C. J. Lawrence et al. (Anaesthesiology 2004) investigated 50 
patients undergoing minor orthopaedic and general surgery. They evaluated 
the anaesthetic requirement and perioperative hemodynamic stability after 
administering single dose of dexmedetomidine 2 μg.kg−1 given before 
induction as intravenous route. The haemodynamic response to tracheal 
intubation and extubation was reduced in the dexmedetomidine group. The 
intra-operative heart rate variability, postoperative analgesic and anti-emetic 
requirements and perioperative serum catecholamine concentrations were also 
lower in the dexmedetomidine group. Hypotension and bradycardia after 
dexmedetomidine at 2 mic/kg infusion was less frequent.  
 
6. M.Virkkilä (Anaesthesiology 2007)43 studied 35 ASA PS patients 
undergoing cataract surgery. The effects of dexmedetomidine on intra-ocular 
pressure, haemodynamic parameters, sedation, anxiolysis and dryness of 
mouth. Dexmedetomidine was used in five doses of 0.25, 0.5, 0.75, 1.0 and1.5 
mic/kg... It was administered intramuscularly 60 min before surgery. 
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Dexmedetomidine at a dose of 1.0 mic.kg−1 produced decrease in intraocular 
pressure in 32% of patients. This dose also induced moderate sedation, but 
was not associated with significant haemodynamic changes. Bradycardia and 
hypotension were observed at1.5 mic/kg. It was concluded that 1.0 μg.kg−1 of 
dexmedetomidine when given intramuscularly as premedication before 
cataract surgery under regional anaesthesia produces sedation. 
Dexmedetomidine at this dose reduces the intra-ocular pressure and produced 
less haemodynamic effects. 
 
7. Poonam S et al (Journal of anesthesiology clinical 
pharmacology) monitored the depth of anesthesia (DOA) using entropy to 
prevent awareness under anesthesia.  ASA I and II patients undergoing 
laparoscopic surgeries were studied. Dexmedetomidine infusion was started at 
1 mcg/kg for 15minutes.it was continued by maintenance infusion of 0.2 
mcg/kg/hr. DOA was monitored with entropy.  Use of dexmedetomidine 
resulted in 62.5% reduction in the induction dose of propofol. 
Dexmedetomidine also decreased end-tidal concentration of isoflurane 
requirement by 30% for maintenance of anesthesia and concluded that 
dexmedetomidine is an effective anesthetic adjuvant that can be safely used 
during laparoscopy without causing awareness. 
 
8. Dyck JB (Anesthesiology.1993)20 observed pharmacokinetics and 
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hemodynamic changes in 10 volunteers after Dexmedetomidine 2 mic/kg 
given by IV or IM route. The bioavailability of dexmedetomidine after IM 
dose was 73 %. After IM administration, the peak concentration was achieved 
in 12 min (2-60 min). The mean peak concentration was 0.81 + 0.27 ng/ml.  A 
Biphasic BP response was observed after IV administration of 
dexmedetomidine. MAP increased by 22% and HR declined by 27% from 
baseline after 5-min after IV infusion of 2 mic/kg dexmedetomidine.  Four 
hours after the infusion, MAP decreased by 20% from baseline and HR 
decreased to 5% below baseline values. Four hours after IM administration, 
MAP decreased by 20% and HR decreased by 10% and concluded that the IM 
administration of dexmedetomidine avoided the acute hemodynamic changes 
seen with IV administration. 
 
9. Jaakola ML(Acta Anesthesiology Scand. 1994)36 investigated in 
20 ASA I-II patients undergoing elective hysterectomy. Ten patients received 
dexmedetomidine 2.5 mic/ kg i.m. 60 min before induction and saline placebo 
i.v 2 min before induction. 10 patients received midazolam 0.08 mg kg-1 i.m. 
60 min before induction and fentanyl 1.5 micrograms kg-1 i.v 2 min before 
induction. Both of the premedication induced comparable sedation, anxiolysis 
and hemodynamic changes to tracheal intubation. Intraoperatively, systolic 
and diastolic BP was 15% and 13% lower in Dexmedetomidine-placebo 
group. The mean heart rate was lower in Dexmedetomidine-placebo group. 
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Fentanyl requirement was more in Midazolam group. The median HR was 3.5 
vs. 2.5 times in Dexmedetomidine vs. placebo group. Postoperative period and 
analgesic requirements were similar in both groups. The author concluded that 
dexmedetomidine premedication offers an attractive alternative to current 
anesthesia practice in elective hysterectomy. 
 
10. Varshali (Indian Journal Anesthesia 2011)12 assessed the 
efficacy of dexmedetomidine in attenuating pressor response to intubation and 
analyzed the reduction in intraoperative anesthetic requirement. 60 patients 
scheduled for elective surgery for more than 3 hours were randomly selected. 
Dexmedetomidine in a dose of 1 mic/kg was given as 10 min infusion before 
the induction of anesthesia. It was continued in a dose of 0.2-0.7 mic/kg/Hr 
until end of procedure. The need for thiopentone and isoflurane was decreased 
by 30% and 32%, respectively, in the dexmedetomidine group as compared to 
the control group. 
 
After tracheal intubation, maximal mean increase in SBP was 8% and 
11% in DBP in dexmedetomidine group, as compared to 40% and 25%, 
respectively, in the control group. Similarly, mean increase in HR was 7% and 
21% in the dexmedetomidine and control groups, respectively. Fentanyl 
requirement during was less in dexmedetomidine group intraoperatively.  The 
conclusion was that perioperative infusion of dexmedetomidine is effective in 
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attenuating pressor response to intubation. It has significant anesthetic and 
opioid sparing effect. 
 
11. Gulay Eren29, (Journal of Anesthesiology Clinical 
Pharmacology. 2011) compared the efficacy and effects of dexmedetomidine 
and midazolam in preoperative sedation. 125 patients in (ASA) I-II were 
divided into 3.dexmedetomidine and midazolam infusions were compared 
with control. 
There was marked sedation and a decrease in anxiety in both midazolam 
and dexmedetomidine group. MAP and HR decreased significantly in 
dexmedetomidine group.  There was no associated hypotension (MAP <60 
mm Hg) or bradycardia (HR <50 bpm). Respiratory rates and SpO2 values 
decreased both groups. Differences in respiratory rates were not significant. 
The author concluded that dexmedetomidine was as effective as higher doses 
of midazolam in sedation. 
 The hemodynamic and respiratory effects were minimal. Although 
dexmedetomidine caused significant decrease in the blood pressure and heart 
rate, it probably just normalized increased HR and BP that was caused by 
preoperative anxiety. 
 
12. Scheinin (Anesthesiology. 1993)11 studied the usefulness of 
dexmedetomidine as preanesthetic agent in 192 ASA PS 1 and 2 patients who 
32 
 
underwent elective abdominal hysterectomy, cholecystectomy, or intraocular 
surgery under general anesthesia. Dose of 2.5 mic/kg dexmedetomidine IM 
administered 60 min before and intravenous saline placebo 2 min before 
induction of anesthesia was compared with a combination of 0.08 mg/kg IM 
midazolam 60 min and 1.5 micrograms/kg intravenous fentanyl 2 min before 
induction or a combination of intramuscular dexmedetomidine and 
intravenous fentanyl. 
 It was observed that dexmedetomidine and midazolam induced 
comparable preoperative sedation and anxiolysis. The dexmedetomidine-
fentanyl combination decreased intubation response more efficiently when 
compared with other two groups. 
The intraoperative fentanyl requirements were greater in midazolam 
patients when compared with other two groups by 53% and 36%. Bradycardia 
was observed more frequently in dexmedetomidine patients (20% in the 
DEXPLA and 33% in the DEXFENT groups) than in MIDFENT patients 
(8%) and they concluded that pretreatment with a single intramuscular 
injection of 2.5 micrograms/kg dexmedetomidine is efficacious, but  increased  
incidence of intraoperative hypotension and bradycardia was observed  in 
ASA PS 1 or 2 patients. 
 
13. Erkola O, (AnesthAnalg. 1994)13studied 192 female patients 
undergoing abdominal hysterectomy. They compared the effects of the 
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i.mdexmedetomidine, and midazolam premedication. The three groups were: 
1) i.m. DEX (2.5mic/kg) and intravenous (i.v) placebo 2) i.m. 
dexmedetomidine and i.v fentanyl (1.5 micrograms/kg) and 3) i.m. midazolam 
(0.08 mg/kg) and i.v fentanyl. 
 
The author observed that the preoperative sedation and anxiolysis was 
comparable in both groups. The maximum BP response to intubation was 
blunted in the patients who received dexmedetomidine-fentanyl combination 
better than the other groups.  However in the two other groups BP increased 
30–34 mm Hg after intubation. 
 
During surgery, bradycardia (heart rate < 40 bpm) was observed in 
6.2% of dexmedetomidine patients, but none of the midazolam patients 
developed any bradycardia. 
Postoperatively 14.1% patients who received dexmedetomidine and 
1.6% of patients who received midazolam had bradycardia. Incidence of 
shivering was less with dexmedetomidine (10%) than with midazolam (52%). 
Author concluded that dexmedetomidine has many desirable effects, but side 
effects such as bradycardia may limit the routine use in ASA PS I-II patients. 
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They studied 107 healthy ASA PS I-II female patients undergoing 
dilatation and curettage. Both premedications were tolerated well without 
haemodynamic or other adverse events. Moderate reductions in BP 
(maximally by 20%) and HR (maximally by 15%) in patient receiving 
Dexmedetomidine .bradycardia occurred in two patients receiving 
dexmedetomidine. Both drugs decreased the plasma concentrations of nor-
adrenaline by 50%, but only dexmedetomidine was effective enough in 
attenuating the catecholamine response to surgery 
 
16. M. Aho, (anaesthesia analgesia1992)41 the author studied 100 
women undergoing gynecologic diagnostic laparoscopy. They studied the 
hemodynamic and endocrine effects of three different doses of 
dexmedetomidine 0.6, 1.2, and 2.4 /μg/kg, oxycodone 0.13 mg/kg and saline 
solution, injected IM 45–60 min before induction. 
 
They observed that HR and MAP increased in all the groups. But the 
maximal MAP after tracheal intubation was lower with dexmedetomidine 2.4-
μg/kg group (104 mm Hg than in the saline solution group 130 mm Hg. 
 
Dexmedetomidine (2.4-and 1.2 μg/kg) attenuated the maximal heart rate 
after intubation (84 and 101 beats/min   respectively) compared with saline 
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solution (116beats/min). On the other hand, 40% of the patients in 
the dexmedetomidine 2.4-μg/kg developed bradycardia. (HR ≥40 beats/ min). 
 
Preoperative anxiety and sedation were evaluated by the patients with 
the aid of a profile of mood-state questionnaire.  Dexmedetomidine 2.4 
(μg/kg) produced significant anxiolysis and sedation.  
 
17. Bajwa et al (Indian journal of anesthesia2012)21 compared 
attenuation of pressor response with dexmedetomidine infusion preoperatively 
and midazolam i.v.o2 desaturation till 94-95% was noted with 
dexmedetomidine. The mean HR and MAP were significantly lower in DEX 
group 20 minutes after infusion. 
 
Laryngoscopy was associated with significant increase in HR and MAP 
in control group. Mean HR and MAP after 1, 3 and 5 min of intubation 
returned to baseline faster with DEX group.  There was no significant 
hemodynamic difference during intraoperative period. 
 
METHODS 
 
This is a double blinded randomized clinical trial done in general 
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surgery theatre in Stanley medical hospital after getting approval from ethical 
committee.The study was conducted from   March 2012 to November 2012. 
60 patients of ASA PS 1 & 2 were randomly assigned into two equal groups 
namely Group M & Group D. 
 
Patients undergoing elective laparoscopic abdominal surgeries were 
enrolled in the study. The randomization was done using sealedenvelope lots 
containing numbers from 1 to 60. Odd numbers were assigned to Group D and 
even numbers were assigned to group M. Randomization and blinding were 
done by an assistant not involved in the study. The assistant diluted the drug 
into 1 ml solution and administered to patients in the pre-anesthetic room. He 
maintained a list containing name of patients, serial number and the group to 
which they belong to. 
 
 
 
 
 
 
INCLUSION CRITERIA: 
 
•Age: between 18 years and 60 years 
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•Sex: both sexes 
•ASA     physical status: I & II  
•Operation: elective  laparoscopic  abdominal  procedures 
 
EXCLUSION CRITERIA: 
 
•Hypertension 
•Pre-existing conduction block 
•Medications (beta blockers, clonidine, MAO inhibitors) 
•Cardiovascular disease31 
•Epilepsy21 
•Chronic obstructive pulmonary disease 
•Child bearing age 
•Intubation attempts lasted more than 25 seconds 
•Diabetes31 
•Difficult airway (modified mallampatti III and IV) 
 
 
MATERIALS 
 
•24 G intramuscular needle and syringe 
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•Injection Dexmedetomidine /midazolam 
•Appropriate size intravenous cannula and I.V. fluids 
•Drugs for General Anesthesia 
•Appropriate size Endotracheal tubes, Other Airway equipments 
•Monitors (pulseoximeter, NIBP, ECG, ETCO2) 
•All Emergency drugs 
 
A complete pre anaesthetic evaluation was carried out in the 
premedication room. The patients were explained in detail, about the effects, 
possible risks and complications of premedication agents. 
 
 The concept of Visual Analog Scale (VAS) for anxiety was explained to 
all the patients under study before surgery. Only those who understood the 
scale and were capable of expressing their anxiety, in terms of the scale were 
included in the study. 
 
Informed written consent was obtained from all patients.Total number 
of patients under study was 60.The sixty patients satisfying the inclusion 
criteria were randomized by drawing enveloped lots. 
 
 The patients were given the drugs as follows: 
GROUP M (n=30):  0.05mg/kg of midazolam diluted to 1 ml with 
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distilled water. 
GROUP D (n=30):  1 mic/kg dexmedetomidine diluted to 1 ml with 
distilled water.  
 
   In the premedication room intravenous access was secured.The 
patients were asked about their anxiety scores in visual analog scale and 
preoperative hemodynamic parameters (HR, SBP, DBP, MAP, and SPO2) 
were noted.  
 
Visual analog scale for anxiety: 
 
This scale was first described by Bond MR and Pilousky in 1966 for 
measuring pain intensity. It uses 10 cm visual scale, one end of which shows 
no pain and the other end showing worst possible pain. The same scale can be 
used to asses’ anxiety, where 0 indicates no anxiety and 10 indicates extreme 
anxiety.   
 
 The study solution was prepared by an assistant, who was not 
associated with the study and intramuscular injection was also given by the 
same. Observations were done by the investigator. 
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 Premedication, either i.m midazolam 0.05mg/kg or i.m 
dexmedetomidine 1 mic/kg was given (according to the group to which they 
belong) in the gluteal region, 60min before surgery. Patients were monitored 
for HR, BP, and SPO2 in the premedication room till they were shifted to 
operating room. Spo2 of the patient was noted at every 10 minutes interval. 
 
 A subjective sedation scale21, derived from the sedation agitation scale, 
was employed for the purpose of evaluation of sedation effect (1=fully awake 
and conscious, 2=awakening on verbal command, 3=awakening on gentle 
shaking, 4=awakening on vigorous shaking and painful stimuli and 
5=unarousable) in our study. This sedation scale was used in our study to 
measure preoperative sedation. 
 
  In the theatre, after recording baseline hemodynamic parameters, 
subjective sedation score and visual analog score for anxiety were noted. 
Inj.Glycopyrrolate 0.2 mg and Inj.fentanyl 2mic/kg were given intravenously 
before induction.  Pre induction hemodynamics was noted. All patients were 
preoxygenated with 100% o2 for 3 minutes. 
 
Induction was done with Injthiopentone 5mg/kg and patients were 
paralyzed with injsuxamethonium 2mg/kg. Laryngoscopy was done with 
Macintosh 3 sized blade and intubation was done with appropriate sized 
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cuffed oral endotracheal tube as quick as possible with vigilant monitoring of 
hemodynamic parameters. All intubations were done by a senior 
anesthesiologist. Those patients in whom the laryngoscopy lasted more than 
25 seconds were excluded from the study. A third person acted as the time 
keeper using a digital stopwatch to measure the intubation time. 
 
Intubation time was the time taken from removal of facemask from the 
patient’s face, till when ventilation was restarted through the endotracheal tube 
and carbon dioxide was detected by capnography. 
 
 Hemodynamic parameters were measured at 1, 2, 3 minutes after 
intubation by the investigator.   
 Maintenance of anesthesia was with N2o 2 liters and 1 liter o2 & 1% 
sevoflurane. Muscle relaxation for surgery was with atracurium 0.5 mg/kg 
initially followed by 0.1mg/kg every 20 minutes. All patients received 
Inj.dexamethsone 0.1mg/kg, 5 minutes after intubation for postoperative 
nausea vomiting prophylaxis. After intubation hemodynamic parameters were 
continuously monitored and recorded at 15 minutes interval till the end of 
surgery. 
 
Mean abdominal pressure was maintained between 10 to 12mm hg & 
ETCO2 between 35-40 mmHg 
43 
 
 
Surgical response in form of raise in HR >20% and rise in MAP > 20% 
from preinduction values when patient was on 1% sevoflurane was given 
injection. Fentanyl -0.5mic/kg i.v bolus.  
 
Sevoflurane concentration (volumes percent) was titrated at 0.2% 
decrements or increments according to change in HR and MAP (>/< 20%) 
from baseline. All patients received Inj.ondensetron 0.1mg/kg 20 minutes 
before the expected extubation time. 
 
Complications like bradycardia (HR <50/min) was treated with Inj 
atropine 0.6mg IV bolus. Hypertension (MAP>20 % of pre-induction value) 
was treated with NTG infusion at a dose of 5 mic/minute. Intraoperative 
hypotension (MAP< 20% of preinduction value) was treated with 2ml/kg of 
ringer lactate with decreasing the volatile agents.  
 
 At the end of the procedure, after establishment of adequate 
spontaneous respiration, injection glycopyrrolate 10mic/kg and injection 
neostigmine 0.05 mg/kg was given intravenously. Patients were extubated, 
after the standard extubation criteria3 was met. Patients were shifted to 
recovery room for further monitoring. 
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POST OPERATIVE MONITORING  
 
Patients were monitored closely in recovery room for 1hr and later in 
post-operative ward for 24 hrs. Visual analog scale for anxiety and sedation 
were observed hourly for two hours.HR, NIBP was recorded every hour for 
two hours and 2nd hourly for 8 hrs and was observed for 24 hours. 
Postoperative pain was managed with Inj.tramadol 2mg/kg i.m when visual 
analog score was more than 4. 
 
 Postoperatively all patients were supplemented with oxygen 5L/min via 
face mask for 4hrs, because it was a laparoscopic surgery. HYPOTENTION 
(<90mmHg SBP) was treated with 2ml/kg bolus of ringer lactate apart from 
usual maintenance fluids. Inj. ondansetron 0.1m/kg was repeated if nausea or 
vomiting occurred. 
 
 
 
 
 
STATISTICAL ANALYSIS 
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A sample size of 30 per group was decided during the pilot study. 
Sample Selection 
Pilot study was done with a sample size of 6 patients in each group, 
before the start of the study to decide on sample size. The mean and standard 
deviation of Intubations was calculated from pilot study.  The sample size was 
calculated based on the formula given in NTI   Bulletin 200646.  
From the pilot study, we got the value of mean and standard deviation, 
the HR change after intubations of Group-D (16.87 ± 2.02) and Group-M 
(18.23 ± 2.86) from baseline values. 
 
       [Z1-α/2 + Z 1-β] 2 (2σ2)   
n=      --------------------------------------               =     (8.98 * 12.26)/ 1.85 = 59.54 
                (d) 2 
 
Z1 -α/2   = 1.96 (5%) 
 Z1-β    = 1.037 (85 % Power) 
 
46 
 
       [Z1-α/2 + Z 1-β] 2 = (1.96 +1.037)2   = 8.98 
 
S= (s1 +s2) / 2              
S = (2.02+2.86)/2 =2.44 
S2 = (2.44)2=5.95 
2 σ2=0.85*2 =12.26 
 
d= (Mean1 –Mean2) 
    = (16.87-18.23) =-1.36 
  d2 = 1.85 
 
From the above calculation sample size was decided as 60 for 2 
samples (30 for each group) 
 
Data was expressed as mean ± SD. Quantitative analysis was compared 
with Student T- test. Equal variance T-Test section for comparison of discrete 
variables and Aspin-Welch Unequal variance test for continuous variables. 
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When using these tests to compare mean among two groups, p-value of 
less than 0.05 was taken as significant. All analyses were done using SPSS 
version 11.5 statistical software. All values were rounded off to a maximum of 
two decimals. 
The patients in each group were comparable in distribution in terms of 
age, weight, and sex distribution. 
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Dexmed 
Mean ± SD 
Mean ± SD DF = 58 
Pre OP 83.93±8.53 81.13±9.42 1.22 0.22
Before 
Induction 61.13±6.52 69.1±7.42 4.49 0.000034* 
Before 
Intubation 65.57±6.47 74.53±8.81 4.57 0.00003* 
Mint 1 75.57±7.13 100.8±8.66 12.54 0.0001* 
Mint 2 77.17±12.36 95.13±9.26 6.48 0.0001* 
Mint 3 67.53±6.36 73.93±7.3 3.68 0.0005* 
Mint 5 69.53±8.36 75.07±6.4 3.42 0.0011* 
Mint 10 70.53±9.36 76.9±7.22 3.69 0.0005* 
Mint 15 77.7±13.46 80.2±6.66 0.93 0.3575 
Mint 30 66.27±10.62 80.87±9.12 5.81 0.0001* 
Mint 45 60.1±6.84 76.6±5.42 10.53 0.0001* 
Hour 1 78.77±9.47 82.6±8.01 1.72 0.09 
Hour 2 73.57±8.34 76.57±6.32 1.596 0.12 
Hour 4 76.93±10.35 82.37±11.28 1.98 0.0526 
Hour 6 78.77±8.74 81.7±8.45 1.34 0.18 
Hour 8 81.03±11.53 83.9±10.4 1.03 0.31 
Hour 10 82.27±9.21 85.77±10.65 1.385 0.17 
 
* Significant 
TABLE 11: 
CHANGES IN SYSTOLIC BLOOD PRESSURE IN mmHg (Mean ± S.D): 
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Blood Pressure at 
Group – 
Dexmed Group – Midaz T – Value 
P – Value 
Mean ± SD Mean ± SD DF = 58 
Pre OP 121.43±10.38 121.00 ± 5.55 0.205 0.84 
Before Induction 113.37±8.95 118.13 ± 5.75 2.46 0.017* 
Before Intubation 113.43±5.37 113.43 ± 5.37 0 1 
Mint 1 120.43±5.35 143.37 ± 6.18 15.626 0.001* 
Mint 2 118.47±10.86 120.90 ± 13.93 0.767 0.45
Mint 3 109.77±7.1 110.63 ± 6.95 0.48 0.63
Mint 5 112.77±7.1 110.77±7.78 1.06 0.3 
Mint 10 114.77±7.1 113.77±7.78 0.53 0.599
Mint 15 128.1±16.75 134.60 ± 9.30 1.86 0.07
Mint 30 118.73±15.94 127.93 ± 15.53 2.397 0.019* 
Mint 45 129.1±18.19 131.40 ± 15.53 0.53 0.6
Hour 1 108.27±6.67 105.4±8.02 1.632 0.108
Hour 2 108.57±6.8 107.57±6.72 0.58 0.56 
Hour 4 105.7±7.97 108.47±6.72 1.477 0.145
Hour 6 107.3±6.02 109.3 ± 6.24 1.28 0.2
Hour 8 109.57±4.92 107.53 ± 6.12 1.44 0.15 
Hour 10 109.7±3.51 109.57 ± 4.93 0.123 0.9
 
* Significant 
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CHANGE IN MEAN DIASTOLIC BLOOD PRESSURE IN 
mm Hg (Mean ±S.D): 
Blood Pressure at 
Group – 
Dexmed Group - Midaz T - value 
P - Value 
Mean ± SD Mean ± SD DF = 58 
Pre OP 80.70 ± 4.36 75.97±6.86 3.245 0.001* 
Before Induction 69.2±6.35 69.47±6.48 0.16 0.87 
Before Intubation 84.20 ± 7.68 81.5±10.22 1.176 0.24 
Mint 1 85.70 ± 7.53 83.57±9.63 0.97 0.33 
Mint 2 90.03 ± 7.16 90.1±7.33 0.036 0.97 
Mint 3 76.87 ±11.34 87.33 ± 11.67 3.58 0.001* 
Mint 5 77.87±11.34 90.33±11.67 4.27 0.00007* 
Mint 10 80.87±11.34 91.33±11.67 3.58 0.00069* 
Mint 15 61.13 ± 11.71 82.83±8.78 8.26 0.0001* 
Mint 30 66.10 ± 8.87 86.97±7.35 10.08 0.0001* 
Mint 45 83.03 ± 7.65 84.63 ± 6.37 0.895 0.374 
Hour 1 76.3 ± 9.92 76.17 ± 9.66 0.05 0.96 
Hour 2 72.57 ± 4.41 72.87 ± 4.60 0.26 0.79 
Hour 4 70.07 ± 6.28 73.67 ± 3.02 2.88 0.0056* 
Hour 6 70.20 ± 6.29 73.03 ± 4.55 2.03 0.047* 
Hour 8 69.57 ± 7.88 74.93 ± 3.44 3.48 0.0009* 
Hour 10 68.30 ± 6.55 75.67 ± 2.62 5.82 0.0001* 
          
        
*Significant 
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TABLE 13: 
MEAN ARTERIAL PRESSURE IN mmHG: 
MAP 
Group –
Dexmed 
Group - 
Midaz T - 
Value 
P – Value
Mean ± SD Mean ± SD DF = 58 
Pre OP 94.28±3.24 90.98±4.78 3.29 0.0018* 
Before Induction 83.92±5.48 85.69±5.23 1.32 0.192 
Before Intubation 93.94±5.85 92.07±6.62 1.09 0.28 
Mint 1 97.28±5.33 103.5±6.93 3.97 0.0002* 
Mint 2 99.51±5.27 100.37±7.02 0.49 .63 
Mint 3 87.83±8.25 95.1±8.54 3.4 0.001* 
Mint 5 89.5±8.25 97.14±8.38 3.61 0.0006* 
Mint 10 92.17±8.25 98.81±8.38 3.18 0.002* 
Mint 15 83.36±10.35 99.91±6.96 7.36 0.0001* 
Mint 30 83.64±7.08 100.22±7.24 9.096 0.0001* 
Mint 45 98.39±7.68 100.22±6.28 1.046 0.3 
Hour 1 86.59±6.32 85.91±97.9 0.4 0.69 
Hour 2 84.57±4.45 84.43±4.62 0.14 0.889 
Hour 4 81.94±4.86 85.27±3.44 3.15 0.003* 
Hour 6 82.57±4.98 85.12±4.16 2.27 0.027* 
Hour 8 82.9±5.45 85.8±3.71 2.62 0.01* 
Hour 10 82.1±4.44 86.97±2.44 5.32 0.000002*
 
*Significant 
63 
 
TABLE 14: 
PREOPERATIVE MEAN OXYGEN SATURATION (in 
%): 
Oxygen Saturation Group – Dexmed Group – Midaz 
Preop 99.43 99.2 
10 mins 98.67 99.13 
20 mins 98.97 98.57 
30 mins 98.6 96.83 
40 mins 98.47 96.43 
50 mins 97.6 96.67 
60 mins 97.6 96.93 
 
 
The mean oxygen saturation in dexmedetomidine group was 
above 98% and 97% with midazolam preoperatively. 
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DISCUSSION 
Ourstudy evaluated the efficiency of midazolam 0.05mg/kg and 
dexmedetomidine 1 mic/kg given as intramuscular premedication in alleviating 
anxiety and inducing sedation in patients undergoing laparoscopic abdominal 
surgeries. 
 
Preoperative anxiety is a challenging concept in the care of patients and 
almost all patients undergoing surgery experience varying levels of anxiety. The 
incidence of preoperative anxiety is 60–80% ii surgical patients. It leads to 
increased catecholamine release.  It is associated with adverse hemodynamic 
responses like hypertension and arrhythmias. 
 
It increases the anesthetic requirement. It decreases patient satisfaction 
with perioperative care39. Sometimes patients may refuse the planned procedure 
because of anxiety. 
Young patients, patients with previous bad anesthetic history, patients 
who have no previous surgical or anesthetic history and female patients are 
more prone to have higher anxiety scores. 
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 Decreasing the preoperative anxiety improves surgical outcome and 
reduces the hospital stay. Relief of anxiety is thus a humane goal and should be 
provided for all patients. 
Benzodiazepines are the drug of choice for preoperative anxiolysis.the 
mechanism by which it causes anxiolysis is that it binds to alpha 2 subunit of 
GABA receptor. The concentration dependent receptor occupancy of 
benzodiazepine is responsible for various drug effects. Anxiolysis is produced 
by 20% receptor occupancy.  
 
Alpha2 agonist like clonidine were found to have sedative and 
anxiolytic property and was widely used as a premedication agent. 
Dexmedetomidine, a selective alpha2 agonist also has sedative anxiolytic 
property. Dexmedetomidine acts at the level of locus ceruleus in inducing 
sedation and anxiolysis. 
 
 There are various methods of assessing preoperative anxiety. It is a 
subjective feeling and so it is more appropriate if the patients describe how they 
feel, preoperatively. In our study, a visual analog scale was used, which is 
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normally used for pain, also allows the patient select a numerical value from 
one to ten to narrate about their anxiety. 
 
In the past, various studies have assessed anxiety in different ways.  
Üstün Y et al used VAS scale for assessing patient satisfaction for sedation 
anxiolysis in preoperative period. They observed that 65% of their patients were 
satisfied with the sedation by Dexmedetomidine than Midazolam.  The 
difference between the two groups was statistically significant. 
 
Alhashemi JA also noted in their study, a significant preference for 
Dexmedetomidine sedation over Midazolam sedation.  They used   7-point 
Likert-like verbal rating scale to measure patient’s satisfaction. 
 
Cristopher et al studied the qualitative aspects of anxiety and revealed 
that three distinct dimensions of preoperative fear exist.  They are fear of the 
unknown, fear of one’s life and fear for feeling ill. In patients with high degree 
of preoperative anxiety, VAS is especially useful to identify specific anesthetic 
concerns 34. 
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Miller et al35compared three different methods of assessing anxiety, the 
VAS, STAI AND HAD (hospital anxiety depression scale). They explained the 
disadvantage of using VAS for the assessment of anxiety.  Patients become 
uncertain about how to respond when using an unfamiliar technique and will 
avoid extreme scores. They crowd responses in the middle range to express 
about their subjective sensation. There is central tendency bias in subjective 
judgment. They concluded that all three scales are equivalent in assessing 
preoperative anxiety,provided the scores are compared to the normative cut off 
values to assess the anxiety. Thus in our study we used VAS for measuring 
preoperative anxiety. 
 
Scheinin H, Jaakola MLin their comparative study observed comparable 
preoperative sedation and anxiolysis for dexmedetomidine and midazolam.  
Olli erkola et al in their study has observed significant increase in 
sedation scores after premedication with both midazolam and 
dexmedetomidine. They used subjective visual analog scale and POMS 
questionnaire for evaluating anxiety and sedation. Both the groups showed 
equal scores for sedation and anxiolysis which is similar to the finding in our 
study13. 
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  A subjective sedation scale21, derived from the sedation agitation scale, 
was employed for the purpose of evaluation of sedation effect (1=fully awake 
and conscious, 2=awakening on verbal command, 3=awakening on gentle 
shaking, 4=awakening on vigorous shaking and painful stimuli and 
5=unarousable) in our study. This scale was previously used in a study by bajwa 
et al. 
Our study evaluated the efficiency of midazolam 0.05mg/kg and 
dexmedetomidine 1 mic/kg given as intramuscular premedication in alleviating 
anxiety and inducing  sedation in patients undergoing laparoscopic abdominal 
surgeries. 
 
In our study we also observed the intubation response, preoperative o2 
saturation, adverse effects and intraoperative analgesia requirement during the 
procedure. 
Intravenous infusion of dexmedetomidine for anxiolysis, sedation and 
attenuating stress response was extensively studied. Though dexmedetomidine 
was very effective, it caused initial hypertension during intravenous infusion 
due to peripheral vasoconstriction. 
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Dyck et al studied the pharmacokinetics of dexmedetomidine after 
intravenous and intramuscular dexmedetomidine in 10 healthy volunteers. They 
observed initial bradycardia and hypertension at 5 minutes after infusion with 2 
mic/kg dexmedetomidine. They observed no such change after intramuscular 
dose of dexmedetomidine20. 
 
  Duration of action after intravenous infusion is less and titration of 
infusion is cumbersome in the preoperative period. Additionally the alpha 
receptor selectivity is dose dependent. Intramuscular route of administering the 
drug needs no such titration and no such biphasic response was observed. The 
alpha 2 receptor sensitivity is well preserved after IM injection due to the steady 
plasma concentration achieved. Hence intramuscular route was chosen for 
premedication in our study. 
 
Virkila et al conducted a dose finding study to assess the optimum dose 
of intramuscular dexmedetomidine. They compared five different doses of 
dexmedetomidine and midazolam premedication for cataract surgery in 35 
patients. They observed that at 1 mic/kg, dexmedetomidine produced moderate 
sedation comparable to midazolam. Dose of 1.5 mic/kg produced significant 
bradycardia43. 
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Scheinin et al’s study also showed similar results. They found 
significant bradycardia and hypotension after 2.5mic/kg intramuscular 
dexmedetomidine premedication with fentanyl 1.5mic/kg IV given 2minutes 
before surgery11. Hence in our study, dose of 1 mic/kg of dexmedetomidine was 
chosen to avoid bradycardia. 
 
  Inthe study, patients with epilepsy were excluded.  Past clinical 
experience suggests that epileptic patients were resistant to the sedative effects 
of dexmedetomidine. The pharmacokinetic interaction between the 
anticonvulsant medications and dexmedetomidine was not well documented. 
The higher dexmedetomidine dose needed to produce sedation may confound 
the results of our study. In the same way, the safety of dexmedetomidine in 
pregnancy was not studied. So child bearing age group was excluded from the 
study. 
 
 Surgical procedure involving laparoscopy was chosen because they are 
associated with significant stress response.  Mean  duration of surgery (minutes) 
were similar in both groups, 47.80+6.13 minutes in group D and 45.97+4.04 
minutes in group M. 
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Midazolam’s role as a sedative, anxiolytic premedication is well 
established. But there is scarcity of literature to support its role in attenuating 
stress response to intubation. H. Ronald Vinik, et al in their study showed that 
midazolam is an efficacious and safe premedication in healthy patients and 
caused minimal tissue irritation32. 
 
 Regarding the safety of dexmedetomidine, it was approved by the FDA 
in 1999. Originally it was approved for use in adults undergoing mechanical 
ventilation in the ICU for 24 hrs. Dexmedetomidine received FDA approval in 
2008 for adult sedation in areas outside the ICU. 
 
 Harry Scheinin MD et al studied about the pharmacodynamics and 
pharmacokinetics of intramuscular dexmedetomidine and stated that the profile 
of intramuscular dexmedetomidine is suited for preanesthetic clinical use and is 
safe11. 
 
Jaakola et al had mentioned that equivalent dose of 2.5 mic/kg of 
dexmedetomidine is 0.08 mg/kg of midazolam10. 
 
74 
 
Harry scheinin et al in their pharmacokinetics and pharmacodynamics 
study of three different doses of intramuscular dexmedetomidine in healthy 
volunteers. The time to peak effect was found to be 1.6 to 1.7 hours. Clearance 
was 0.7 to 0.9 L/hr/kg. The volume of distribution was 2.1 to 2.6 L /kg. 
 
Dyce et al in their study have given totally different results. Time to 
peak effect after intramuscular injection was 16 minutes20. 
 
 Elimination half-life after intramuscular dexmedetomidine is 1.6 to 2.4 
hours13. The serum concentration of dexmedetomidine follows linear 
relationship with intramuscular dose. Intramuscular dexmedetomidine acts 
longer than intravenous route. 
Barsan, William G et al in their study showed that time to peak effect 
after intramuscular midazolam was 19.6 minutes.40.Elimination half life was 2.5 
hours.  Volume of distribution was 1.5 L/kg. Clearance was 0.39 L/hr/kg. 
 
Olli Erkola et al and M.Aho et al   have studied the usefulness of 
intramuscular route of dexmedetomidine. Bajwaet al21 found that it is tolerated 
well without any local reaction at injection site. Similarly in our study also, no 
patients developed any reaction to dexmedetomidine or midazolam. 
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 The time needed to achieve clinically relevant sedation in adults after 
intramuscular administration of dexmedetomidine is not documented in any 
study. Most studies describe intramuscular administration 45–60 minutes before 
induction of anesthesia.  
 
Intramuscular premedications are administered 45 -60 minutes before 
the procedure. Olli Erkola et al in his study has administered the premedication 
45-90 minutes before the surgery.  M.Aho et al administered the drug 45-60 
minutes before the surgery. R. Aantaa et al in his study administered at 60 
minutes before the surgery. In our study also we have given premedication 60 
minutes before the surgery. 
 
Our study showed comparable sedation and anxiolysis preoperatively as 
assessed by subjective sedation score and visual analog score for anxiety with 
dexmedetomidine and midazolam intramuscular premedication. The difference 
between them was statistically not significant (p=0.28) for sedation score and 
(p=0.53) for VAS for anxiolysis respectively. This finding of ours is 
contradictory to that found with M.Aho et al. 
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M.Aho et al observed that only at doses of 2.4 mic/kg dexmedetomidine 
IM produce significant anxiolysis and sedation41. The sedation and anxiolysis 
was assessed by mood state questionnaire. 40% patients received atropine for 
bradycardia at this dose. 
 
 Patients who were given midazolam, were more drowsy, but responded 
with higher VAS for anxiety after extubation giving a statistically significant 
difference at this time. This shows dexmedetomidine causes more clear headed 
recovery than midazolam premedication. Both drugs produced equal subjective 
sedation score and VAS at one and two hours after extubation. 
  
Though comparing dexmedetomidine and midazolam produces 
comparable sedation and anxiolysis, dexmedetomidine lacks amnestic 
property15, which is there for midazolam. This amnestic property of midazolam 
is preferred one in the perioperative setting. 
 
Hsu et al30 and yungwei31have demonstrated in healthy volunteers that 
ventilatory effect to hypercapnia is not affected even when patients become 
unresponsive to vigorous stimuli. Dexmedetomidine exhibit arousal response to 
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hypercapnia which is similar to the normal sleep and is a safety feature with this 
drug. 
Gulayet al29 observed more desaturation with midazolam 0.06 mg/kg 
compared to 1mic/kg dexmedetomidine infusion preoperatively. 
Bajwaet al21 in their study on the contrary, have observed o2 
desaturation after dexmedetomidine infusion preoperatively to values as low as 
94-95%. This desaturation immediately disappeared after waking the patients 
up. These findings are contrasting to those in our study. 
In our study,the o2 saturation measured preoperatively after 
administration of IM premedication was analysed. It was observed that the 
mean o2 saturation in patients who received dexmedetomidine (1 mic/kg IM) 
was well above 97% at all times before shifting the patient to the operating 
room. 
  In patients who received midazolam (0.05 mg/kg IM), the mean o2 
saturation dropped till 96%. But the actual spo2 of patients in midazolam group 
dropped to  93%, whereas in dexmedetomidine group in no patient the spo2 
went below 95%. 
 
Reid and Brace were the first to report the hemodynamic responses to 
laryngeal and tracheal stimulation in an anesthetized patient.  Attenuation of 
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these pressor responses has been one of the most often researched areas in 
anaesthesia. Suppression of stress response is associated with significant 
incidence of side-effects.  
 
Stress response after laryngoscopy is due to reflex sympathetic 
stimulation caused by pharyngeal and laryngopharyngeal stimulation. The 
increased sympatho-adrenal activity results in increase in heart rate and blood 
pressure and increases the risk of arrhythmias.  This tachycardia and 
hypertension are only transient and unpredictable. Although these changes are 
not detrimental in healthy individuals, it may be disastrous in patients with 
hypertension, ischemic heart disease, valvular heart disease and old age. 
 
This stress response to intubation will be exaggerated when duration of 
laryngoscopy is prolonged and the force used for laryngoscopy is 
high. Hypertension starts within five seconds of laryngoscopy, peaks in 1-2 min 
and returns to baseline within 5 min. 
 
 A variety of drugs have been used to control the hemodynamic 
response, such as vasodilators, beta blockers, calcium channel blockers, 
alpha2 agonists and opioids. No modality was without any side effect22.  
79 
 
In the past, alpha2 agonist like clonidine was extensively used for 
attenuation of sympathoadrenal stimulation caused by tracheal intubation and 
surgery.  Dexmedetomidine is the new alpha-2 agonist having 8 times more 
affinity for alpha-2 adrenoceptors when compared to clonidine. 
Dexmedetomidine has shown only partial agonistic activity and is known to 
decrease the plasma catecholamine. It also suppresses the release of 
catecholamine after any stress26, 42, and 28.Dexmedetomidine does not alter the 
catecholamine synthesis, storage or metabolism, nor does it block any receptors.  
Thus it provides the possibility of reversing the hemodynamic effects with 
vasoactive drugs15. 
 
Similarly in our study, the mean heart rate at 1, 2 and 3 minutes after 
intubation was less than preoperative heart rate by 10beats/minute in 
dexmedetomidine group. However in midazolam group, there was an increase 
in mean heart rate after intubation, when compared to preoperative value by 
7beats/minute.  
 
There was statistically significant (p=0.0002) and (p=0.001) difference 
in mean arterial pressure at first and third minuteafter intubation respectively. 
Dexmedetomidime blunted the intubation response, although not effectively at 
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second minute after intubation. The systolic BP was less in dexmedetomidine 
group in the first minute after intubation, the difference being statistically 
significant (p=0.001).  The diastolic BP was less in dexmedetomidine at third 
minute when compared to midazolam group.  
 
Bajwa et al showed an increase in systolic BP after intubation. It was 
8% in DEX,but in MID group it is 40%. Rise in diastolic BP were 11% in DEX 
compared to 25% in MID group after intubation. Thus dexmedetomidine did not 
completely obtund the pressor response to intubation21. This finding frombajwa 
et al’s study is in line with that of ours, with respect to MAP response at 2 
minutes after intubation. 
 
The study by Bajwaet al21 shows that the mean HR was significantly 
lower in patients who received dexmedetomidine infusion after 20 minutes. 
After laryngoscopy, the HR raised significantly in both the groups. The rate of 
return of mean HR to baseline values and hemodynamic stabilisation was 
significantly early in dexmedetomidine group. 
 
Varshaliet al10 showed that preoperative dexmedetomidine infusion 
resulted in decrease in HR of 7% compared to 21% in midazolam group. 
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HR response to intravenous infusion is studied in all the above 
mentioned studies. However  studyby  Scheinin H, Jaakola ML showed that 
dexmedetomidine IM and fentanyl IV combination blunted intubation response 
more efficiently than dexmedetomidine-placebo and midazolam-fentanyl 
groups, in which approximately 15 beats/min greater increases were observed. 
 
Aanta et al studied in 107 patients undergoing cervical dilatation and 
curettage. They observed hemodynamic changes after intramuscular 
dexmedetomidine 1 mic/kg and midazolam 0.08 mg/kg 60 minutes before the 
procedure.  Heart rate response to intubation was decreased   by 15%. 
Bradycardia (<45beats/min) occurred in two patients who received 
dexmedetomidine. 
 
Regarding intraoperative hemodynamics, the heart rate was significantly 
less in dexmedetomidine group when compared to midazolam group. Mean 
arterial pressure was less intraoperatively in dexmedetomidine group when 
compared to midazolam. There was a rise in MAP after extubation in both the 
groups, which means that extubation response was not effectively blunted by 
both the premedication agent at the given dose. 
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The analgesic effect of dexmedetomidine is due to its action on alpha 2 
receptors in locus ceruleus and spinal cord.  Narcotic sparing effect is seen after 
systemic use of dexmedetomidine. 
 
Varshaliet al10 analgesic requirement was 33% more with midazolam 
group when compared to dexmedetomidine. . 
 
Scheinin H, Jaakola ML11showed that the intraoperative fentanyl 
requirements were greater in patients who received midazolam fentanyl 
combination. In dexmedetomidine fentanyl combination group, the analgesic 
requirement was 56% lesser and dexmedetomidine placebo group it is 31% 
lesser than midazolam fentanyl group. 
 
 In our study, patients belonging to dexmedetomidine group one patient 
needed fentanyl top up intraoperatively. However five patients in midazolam 
group needed fentanyl. The difference between the two groups were statistically 
significant.(p=0.019). 
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Bradycardia, hypotension, hypertension are the common side effects of 
dexmedetomidine.44 
 
Scheinin et al have observed that patients in dexmedetomidine group 
required glycopyrrolate for bradycardia and fluids and vasopressors for 
hypotension more often than midazolam group.  Intraoperatively the incidence 
of bradycardia in patients who received dexmedetomidine alone was 20% and 
in those who received dexmedetomidine-fentanyl combination was 33%. It was 
only in 8% of the patients in midazolam group. 
 
In our study, 17% of patients in dexmedetomidine group, developed 
bradycardia(HR<50/minute) and were treated with Inj.atropine 0.6mg 
intravenously. Hypotension occurred in 7% of patients of patients in 
dexmedetomidine group and in no patients in midazolam group.  
 
Post operative nausea vomiting is an unpleasant event for the patients. 
Kalkman23 Preoperative anxiety    showed statistically significant but weak 
correlation with increased the incidence of PONV. Laparoscopic surgeries are 
associated with significant post operative nausea and vomiting24. Hence, in our 
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study we had given inj.dexamethasone and inj.ondensetron for PONV 
prophylaxis. 
 
Midazolam, apart from its anxiolytic effect, additionally has decreased 
incidence of postoperative nausea vomiting when given as intravenous 
premedication33. Dexmedetomidine, although it has numerous anesthetic 
adjuvant properties, it is found to increase the gastric empting time and 
intestinal transit time at the dose of 1 mic/kg infusion.44Scheinin et al observed 
no difference in the incidence of nausea vomiting in both dexmedetomidine and 
midazolam groups in their study11. 
 
In our study, out of sixty patients, two patients in dexmedetomidine 
complained of nausea immediately after extubation and two other patients had 
vomiting after extubation . Patients in midazolam group had no vomiting, but 
two patients had nausea. Thus incidence of nausea was similar in both the 
groups. Seven patients in dexmedetomidine group had vomiting. But incidence 
of vomiting is higher with patients receiving dexmedetomidine undergoing 
laparoscopic surgeries. 
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Shivering is a protective phenomenon by which our body tries to 
compensate for the heat lost during surgery. Postoperative shivering has number 
of adverse effects. It increases the risk of incidental trauma, interferes with 
monitoring, and increases the O2 consumption and co2 production by 200%. It 
increases the minute ventilation and cardiac output, which render those patients 
with limited reserve at and more risk of respiratory and cardiac failure. 
 
Dexmedetomidine decreases the incidence of postoperative  shivering 
when given at 1 mic /kg as intravenous infusion before surgery37 as observed by 
sukhmindher et al. Erkola et al also in their study observed a decreased 
incidence of postoperative shivering in patients who received 2.5 mic/kg IM 
dexmedetomidine premedication13. The incidence of postoperative shivering 
was 10% after DEX and 52% after midazolam. 
In our study, the incidence of shivering was 7% in midazolam group and 
none in dexmedetomidine group. 
 
The mechanism by which dexmedetomidine decreases the shivering 
seems to be central in nature. It decreases shivering threshold and 
vasoconstriction. It also decreases the central thermal sensitivity by decreasing 
neuronal conductance38. 
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 In our study incidence of bradycardia was 1hour 45 minutes which 
corresponds to the time to peak effect of dexmedetomidine. No bradycardia was 
observed after 3hours of injection. No incidence of bradycardia in midazolam 
was observed intraoperatively and postoperatively.  
 
This finding is similar to those by Scheinin H, Jaakola M.L 11 et al 
andolliErkolaet al13. . V.G.Yezbek.karan. (MEJ Anesth2006)31has clearly 
mentioned in his article the specific indications of dexmedetomidine 
premedication. Alcohol abuse, opioid tolerance, patients susceptible to the 
perioperative stress response and hypertensive patients are the group of patients 
who will specifically benefit from dexmedetomidine premedication. 
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SUMMARY 
Dexmedetomidine, a selective alpha 2 agonist has multitude of roles in 
anaesthesia.  Its sedative, anxiolytic and anesthetic sparing action favour its use 
as a premedicant. Our prospective randomized double blinded study was 
designed to assess whether dexmedetomidine is as efficient as midazolam in 
controlling anxiety and inducing sedation in patients undergoing laparoscopic 
abdominal surgeries. 
Our observations were 
• Dexmedetomidine is equally effective in inducing 
preoperative sedation and allaying anxiety, when compared to 
midazolam when given at a dose of 1 mic/kg 60 minutes before 
surgery. 
• Oxygen saturation in the pre anesthetic room, after 
dexmedetomidine intramuscular premedication was well preserved 
above 95%, while it decreased to 93% in midazolam group. 
• Intubation response in terms of heart rate is better 
blunted by dexmedetomidine (1 mic/kg) IM than midazolam (0.005 
mg/kg). The difference between the two groups being statistically 
significant. 
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• Intubation response in terms of MAP was better 
blunted in dexmedetomidine group than midazolam group. Also 
the maximal increase in BP after intubation was less in patient who 
received dexmedetomidine premedication. 
• Intraoperative analgesia requirement was less in 
dexmedetomidine group, when compared to midazolam. Only 
3.33% of patients in group D required fentanyl intraoperatively. In 
group M, 20% of patients needed analgesia. The difference 
between them was statistically significant. 
• The incidence of bradycardia (HR<50/min) was 17% 
in group D, whereas no such incidence occurred in group M. 
•  Hypotension was 7% with group D, whereas it 
occurred in none patient in group M. 
• Incidence of postoperative shivering was significantly 
higher with group M (7%) when compared to group D where none 
had shivering. 
•  Incidence of nausea was similar in both groups. 
Incidence of vomiting was significantly higher with 
dexmedetomidine (7%) premedication, when compared with 
midazolam (0%). 
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CONCLUSION 
 
It is concluded that premedication with a single intramuscular injection 
of 1micrograms/kg dexmedetomidine is as efficacious as midazolam 0.05 
mg/kg given intramuscularly inproducing sedation and anxiolysis in patients 
undergoing laparoscopic abdominal surgeries. 
 
 It is also efficacious in blunting the hemodynamic response to 
intubation, reducing the intraoperative analgesic requirement. 
Dexmedetomidine causes significant increase in the incidence of intraoperative 
bradycardia and hypotension at 90 minutes after intramuscular injection in ASA 
physical status 1 or 2 patients undergoing laparoscopic abdominal surgeries. 
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   PROFORMA 
 
 
DATE:                                                                    SERIAL NO: 
 
Name:               Lot number: 
 
Age/Sex/Weight: 
 
Group assigned: M/D  
 
I.P Number: 
 
Diagnosis: 
 
Surgery planned: 
 
ASA PS:                                         Duration of Surgery 
 
Associated medical condition: 
 
 
PREOPERATIVE PARAMETERS                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
HR 
 
MAP  
SPO2  
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OXYGEN SATURATION 
 
 
 
 
   TIME(IN MIN       
AFTER PREMEDICATION) 
1
0 
2
0 
3
0 
 
 
4
0 
 
 
5
0 
6
0 
 
 
   O2 SATURATION 
  
 
 
 
Induction:  
Inj.thiopentone:  ___________   mg. 
 
Inj.succinylcholine:  ___________   mg. 
 
Intubation:   ___________mm  ETT:     
 
DURATION OF LARYNGOSCOPY (MIN): 
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PARAMETERS R BP 
D
BP 
M
AP Analgesia
BEFORE INDUCTION  
 Before intubation  
1 min after intubation  
2 min after intubation  
 
3 min after intubation  
 
5 min after intubation  
10  min after intubation  
15 min  
30min  
45min  
1 hr  
2 hr  
4hr  
6hr  
8hr  
10hr  
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Sedation /Anxiety VAS score 
 
 
INCIDENCE OF SIDE EFFECTS: 
 
 
1)  BRADYCARDIA:  YES/NO 
 
TREATED WITH: 
 
2)  HYPOTENSION:  YES/NO 
 
TREATED WITH: 
 
3)  SHIVERING:  YES/NO 
 
TREATED WITH: 
 
4)  NAUSEA/VOMITING: 
 
TREATED WITH: 
 
5)  OTHERS: 
  Parameters SSScore VAS 
Baseline  
    --------------- 
 
Before induction   
After extubation 
 
  
1 hour after extubation   
2 hour after extubation   
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Sl. No order Date Name Age Sex Wt Diagnosis
1 12.6.12  Eswari 18 F 68 sub acute appendicitis
2 12.6.12 Palani 19 M 52 sub acute appendicitis
3 15.6.12 Fathima 21 F 66 sub acute appendicitis
4 19.6.12 Gopi 20 M 50 sub acute appendicitis
5 20.6.12 Devi kala 18 F 64 sub acute appendicitis
6 25.6.12 Chitra 22 F 56 sub acute appendicitis
7 27.6.12 Kanagu 16 M 48 sub acute appendicitis
8 27.6.12 Sathish 23 M 51 sub acute appendicitis
9 02.7.12 Abirami 19 F 63 sub acute appendicitis
10 04.7.12 Sundar 27 M 47 sub acute appendicitis
11 10.7.12 Sumathi 28 F 60 adhesive colic
12 12.7.12 Arokiya das 19 M 65 sub acute appendicitis
13 17.7.12 Swetha 26 F 53 sub acute appendicitis
14 17.7.12 Sultan 19 M 58 sub acute appendicitis
15 18.7.12 Anitha 25 F 62 sub acute appendicitis
16 23.7.12 Saravanan 23 M 54 sub acute appendicitis
17 25.7.12 Banumathi 22 F 57 sub acute appendicitis
18 27.7.12 Kumaran 31 M 64 sub acute appendicitis
19 30.7.12 Hema devi 30 F 55 sub acute appendicitis
20 31.7.12 Suganthi 24 F 61 sub acute appendicitis
21 31.7.12 Malliga 23 F 55 sub acute appendicitis
22 02.7.12 Padma 31 F 63 sub acute appendicitis
23 17.8.12 Murugesan 30 M 59 sub acute appendicitis
24 23.8.12 Selvam 28 M 51 sub acute appendicitis
25 25.8.12 Ram kumar 19 M 59 sub acute appendicitis
26 28.8.12 Lakshmi 25 F 61 sub acute appendicitis
27 30.8.12 Ravi 24 M 63 sub acute appendicitis
28 30.8.12 Ratha 18 F 56 sub acute appendicitis
29 31.8.12 Gopal 32 M 62 sub acute appendicitis
30 31.8.12 Usha 22 F 58 sub acute appendicitis
Mean 23.40 23.40
Stdev 4.58 5.58
master chart Group D ( dexmedetomidine)
SSS
Procedure ASA Status Duration before ind       preop PreOP before ind
Laproscopic Appendicectomy I 45 2 4 3
Laproscopic Appendicectomy I 50 2 3 1
Laproscopic Appendicectomy I 45 2 3 1
Laproscopic Appendicectomy I 40 2 4 3
Laproscopic Appendicectomy I 45 2 3 2
Laproscopic Appendicectomy II 50 2 4 4
Laproscopic Appendicectomy I 45 2 4 3
Laproscopic Appendicectomy I 50 2 5 3
Laproscopic Appendicectomy I 50 2 3 3
Laproscopic Appendicectomy I 40 2 3 1
 laproscopic  adhesiolysis I 45 2 3 1
Laproscopic Appendicectomy II 50 2 4 2
Laproscopic Appendicectomy I 60 3 3 1
Laproscopic Appendicectomy I 50 2 3 3
Laproscopic Appendicectomy I 50 2 4 2
Laproscopic Appendicectomy I 55 2 3 2
Laproscopic Appendicectomy II 45 2 4 1
Laproscopic Appendicectomy I 45 2 5 2
Laproscopic Appendicectomy I 45 2 3 2
Laproscopic Appendicectomy I 40 2 5 3
Laproscopic Appendicectomy I 40 2 3 1
Laproscopic Appendicectomy I 44 2 3 2
Laproscopic Appendicectomy I 45 2 3 1
Laproscopic Appendicectomy I 40 2 5 2
Laproscopic Appendicectomy I 45 2 5 3
Laproscopic Appendicectomy I 50 2 4 3
Laproscopic Appendicectomy II 50 2 6 1
Laproscopic Appendicectomy I 50 2 6 2
Laproscopic Appendicectomy I 60 2 5 2
Laproscopic Appendicectomy I 65 2 3 2
47.80 2 3.87 2.07
6.13 0.18 0.97 0.87
VAS
o2 saturation
Intubation preop 10min 20min 30min 40min 50 min 1 HR Preop BI BIN 1 min
20 100 98 100 97 98 95 96 66 55 55 88
25 100 98 99 99 99 97 95 84 65 64 73
15 100 99 98 98 99 97 95 65 56 62 65
18 99 99 99 98 99 99 96 79 58 66 63
16 100 98 100 99 99 98 99 74 60 64 67
10 99 99 99 99 99 98 99 66 55 58 68
15 100 98 98 98 99 97 98 89 60 66 76
12 99 99 99 98 98 96 97 73 64 72 74
18 99 98 98 98 98 98 96 82 66 70 75
18 99 99 99 99 97 97 96 88 59 66 85
15 100 98 99 99 99 98 95 93 56 65 76
20 99 99 100 99 97 99 96 85 66 62 69
18 99 99 99 98 99 97 97 84 71 78 71
20 100 100 99 98 99 99 98 88 60 67 70
20 99 99 98 98 98 97 99 88 66 62 78
20 99 99 100 99 99 99 98 74 58 63 75
18 99 99 98 99 99 99 99 92 55 52 67
15 100 99 99 98 99 97 98 99 52 66 68
15 99 99 100 100 98 98 99 88 53 56 77
16 100 98 99 99 99 98 98 93 62 70 76
20 99 99 98 98 97 99 98 90 58 62 77
18 100 98 99 99 97 98 99 85 51 59 76
15 99 99 100 100 99 99 99 89 69 75 70
15 100 99 99 99 97 96 98 82 62 70 78
25 99 99 98 98 99 96 98 80 69 68 88
18 100 99 99 99 99 96 98 91 64 69 85
20 99 98 98 98 99 98 99 89 56 59 78
18 99 98 99 99 98 99 98 84 62 68 87
18 99 99 99 99 99 96 98 90 76 79 88
25 100 98 100 99 99 98 99 88 73 74 79
17.87 99 99 99 99 98 98 98 83.93 61.23 65.57 75.57
3.45 #REF! #REF! #REF! 0.50 0.55 0.72 0.67 8.53 6.35 6.47 7.13
2 min 3 min 15 min 30min 45min 1hr 2hr 4hr 6hr 8hr 10hr Preop BI BIN 1min
87 61 65 68 58 88 68 88 76 66 77 123 109 116 132
96 74 76 78 48 90 86 86 86 86 90 132 112 110 140
88 65 48 80 62 88 76 94 82 84 86 124 100 120 155
95 60 78 76 64 82 70 82 84 88 86 98 124 116 145
79 70 76 72 46 78 80 80 80 82 82 109 126 120 137
96 62 66 49 52 80 70 84 82 84 86 122 108 106 128
89 69 88 78 58 90 86 99 96 100 103 110 124 122 140
90 68 88 78 62 88 82 82 85 90 88 132 124 120 150
98 78 69 54 55 58 48 64 59 56 68 116 108 104 142
90 58 46 86 56 78 68 74 78 76 78 128 98 114 132
72 62 90 86 66 80 72 78 80 80 78 132 95 116 132
68 60 78 62 64 98 73 94 95 96 98 98 114 106 142
91 60 80 59 68 64 83 62 66 62 66 111 118 114 138
72 72 80 61 44 84 87 84 85 88 84 115 116 112 121
70 72 50 65 62 78 77 72 72 72 74 136 108 104 116
58 70 72 66 61 68 70 72 72 74 72 112 118 112 138
69 84 86 45 68 66 76 59 67 69 78 130 102 116 130
61 76 60 56 54 80 68 84 83 84 82 138 108 104 122
69 72 78 54 52 68 72 70 66 68 68 128 118 116 132
68 65 84 64 60 82 73 82 84 84 82 120 108 104 128
78 73 88 59 65 88 74 72 70 84 90 128 124 112 130
88 68 86 55 58 77 80 74 76 99 87 112 119 114 122
72 66 98 66 62 73 80 65 74 93 89 116 124 114 150
68 68 83 69 66 71 75 89 93 73 95 128 119 116 140
66 58 83 62 66 66 75 63 74 73 96 120 107 120 147
56 64 86 58 60 92 58 63 74 76 70 117 107 121 139
66 63 100 65 62 83 66 74 73 66 80 132 130 112 138
76 64 91 72 70 79 67 74 81 90 75 126 116 113 146
67 69 78 80 71 76 67 72 84 100 77 118 107 113 133
72 75 80 65 63 70 80 72 86 88 83 132 110 116 140
77.17 67.53 77.70 66.27 60.10 78.77 73.57 76.93 78.77 81.03 82.27 121.43 ### ### ####
12.36 6.36 13.46 10.62 6.84 9.47 8.34 10.35 8.74 11.53 9.21 10.38 8.95 5.37 9.29
Pulse rate
2min 3min 15min 30min 45min 1hr 2hr 4hr 6hr 8hr 10hrs Preop BI BIN 1 min
122 110 90 126 116 124 118 112 108 114 110 88 72 94 93
124 108 89 98 126 104 110 108 102 108 112 82 70 86 84
129 120 102 115 100 112 108 106 112 108 104 86 68 92 94
132 112 112 129 118 108 120 116 106 120 110 90 64 82 80
101 122 119 140 130 114 116 110 98 116 108 84 82 82 84
98 106 94 134 125 100 98 100 110 104 109 80 78 84 87
129 122 119 140 126 108 112 118 116 118 115 84 77 96 100
99 110 118 89 135 118 116 122 98 116 115 80 74 90 86
132 100 135 102 140 98 100 102 104 104 103 84 76 80 83
142 112 134 118 144 114 110 108 110 110 107 80 65 80 91
98 100 142 100 124 94 106 110 114 108 112 74 69 86 90
125 100 148 128 115 98 100 102 116 104 115 80 69 96 92
134 112 139 129 148 110 112 108 99 108 109 84 63 65 68
109 108 129 104 144 100 98 102 110 108 103 78 75 83 80
130 100 138 135 160 96 98 100 110 100 110 70 61 76 87
99 102 129 104 89 110 108 114 108 112 113 84 63 74 80
135 118 119 110 98 112 110 114 103 110 111 82 58 90 87
128 98 137 94 98 102 100 100 106 104 111 78 54 82 86
124 114 148 119 150 104 102 108 114 110 110 74 66 70 74
122 106 142 120 133 92 108 104 117 108 109 76 64 82 85
125 113 148 140 145 104 102 102 102 109 114 80 77 96 92
124 112 135 135 145 110 114 102 114 115 107 83 76 90 83
122 112 137 100 140 118 110 108 100 115 105 83 66 86 100
130 100 129 94 129 100 96 106 100 104 108 74 66 76 80
132 109 145 129 144 100 109 100 109 106 110 80 69 90 87
110 108 128 122 138 96 112 120 105 112 113 80 69 90 83
134 120 140 110 99 107 110 115 97 115 114 84 69 83 87
131 120 142 140 127 114 100 122 106 108 109 82 76 76 69
125 107 127 130 148 98 108 110 110 103 104 77 73 81 95
110 112 129 128 139 105 116 105 115 110 111 80 75 88 84
#### 109.77 128.10 107.30 ### 80.70 69.47 84.20 85.70
12.66 7.10 16.75 15.94 18.19 7.95 6.72 6.72 6.02 4.92 3.51 4.36 6.48 7.68 7.53
Systolic Blood Pressure
2 min 3 min 15 min 30min 45 min 1 HR 2 HR 4 HR 6 HR 8 HR 10 HR Preop BI BIN 1 min 2 min
92 64 48 55 88 92 76 70 76 77 74 100 84 101 106 102
88 78 60 56 84 94 82 78 66 80 66 99 84 94 103 100
92 76 55 60 86 90 68 72 88 79 60 99 79 101 114 104
83 85 57 67 88 88 84 78 70 72 68 93 84 93 102 99
86 80 48 59 92 78 74 72 76 82 66 92 97 95 102 91
90 58 55 59 90 78 64 72 66 68 58 94 88 91 101 93
102 96 58 64 94 88 80 76 72 76 60 93 93 105 113 111
84 54 68 72 88 87 70 67 70 67 65 97 91 100 107 89
88 80 66 62 78 68 74 76 71 76 70 95 87 88 103 103
92 88 72 74 88 67 68 57 68 58 66 96 76 91 105 109
94 88 60 78 87 73 74 66 70 60 64 93 78 96 104 95
94 76 57 67 85 75 74 67 76 68 58 86 84 99 109 104
70 56 50 58 76 66 72 68 67 65 64 93 81 81 91 91
84 66 90 78 96 65 68 59 68 65 63 90 89 93 94 92
90 76 88 82 69 62 68 74 86 85 88 92 77 85 97 103
82 86 65 67 79 76 74 70 74 80 73 93 81 87 99 88
98 68 56 69 78 75 76 78 78 76 67 98 73 99 101 110
90 65 58 56 85 82 74 72 68 66 68 98 72 89 98 103
78 70 76 74 80 78 68 72 68 70 64 92 83 85 93 93
88 84 75 55 82 66 68 69 65 64 72 91 79 89 99 99
103 80 46 56 64 88 70 76 72 79 80 96 93 101 105 110
88 78 55 64 86 87 70 76 68 60 72 93 90 98 96 100
84 75 47 67 79 68 72 60 67 59 75 94 85 95 117 97
102 84 44 79 85 67 68 68 60 72 65 92 84 89 100 111
100 63 55 65 85 82 74 70 71 66 68 93 82 100 107 111
98 73 56 60 93 66 74 76 66 67 66 92 82 100 102 102
94 88 57 68 66 64 80 58 65 64 69 100 89 93 104 107
88 92 67 56 83 76 74 59 60 55 70 97 89 88 95 102
88 96 68 88 78 66 74 76 64 65 78 91 84 92 108 100
93 83 77 68 79 73 74 70 70 66 72 97 87 97 103 99
90.10 76.87 61.13 66.10 83.03 #### #### #### #### #### 68.30 94 84 94 103 101
7.33 11.34 11.71 8.87 7.65 9.66 4.60 6.27 6.29 7.88 6.55 3.24 5.93 5.85 6.08 6.92
Diastolic Blood Pressure
3 min 15 min 30min 45 min 1 HR 2 HR 4 HR 6 HR 8 HR 10 HR ANALGESIA  SIDEEFECT
79 62 79 97 103 90 84 #REF! 89 #REF!
88 70 70 98 97 91 88 #REF! 89 #REF! brady
91 71 78 91 97 81 83 #REF! 89 #REF!
94 75 88 98 95 96 91 #REF! 88 #REF! Nausea
94 72 86 105 90 88 85 #REF! 93 #REF! brady
74 68 84 102 85 75 81 #REF! 80 #REF!
105 78 89 105 95 91 90 #REF! 90 #REF!
73 85 78 104 97 85 85 #REF! 83 #REF!
87 89 75 99 78 83 85 #REF! 85 #REF! brady
96 93 89 107 83 82 74 #REF! 75 #REF!
92 87 85 99 80 85 81 83 76 #REF! Vomiting
84 87 87 95 83 83 79 85 80 #REF!
75 80 82 100 81 85 81 82 79 #REF!
80 103 87 112 77 78 73 81 79 #REF! brady
84 105 100 99 73 78 83 90 90 #REF!
91 86 79 82 87 85 85 86 91 #REF!
85 77 83 85 87 87 90 91 87 #REF! brady
76 84 69 89 89 83 81 78 79 #REF!
85 100 89 103 87 79 84 80 83 #REF!
91 97 77 99 75 81 81 80 79 #REF!
91 80 84 91 93 81 85 86 89 #REF!
89 82 88 106 95 85 85 84 78 #REF! Vomiting
87 77 78 99 85 85 76 78 73 #REF!
89 72 84 100 78 77 81 77 81 #REF!
78 85 86 105 88 86 80 84 80 #REF!
85 80 81 108 76 87 91 80 80 #REF!
99 85 82 77 78 90 77 78 75 #REF!
101 92 84 98 89 83 80 75 72 #REF! Nausea
100 88 102 101 77 85 87 81 80 #REF!
93 94 88 99 84 88 82 86 82 #REF!
88 83 84 98 86 84 83 #REF! 83 #REF!
8.25 10.50 7.08 7.68 7.93 4.62 4.56 #REF! 5.84 #REF! #DIV/0!
#NAME?
MAP
Hypotension
TREATMENT
79.73333333
78.93333333
78.93333333
74.13333333
73.86666667
75.2
74.13333333
77.86666667
75.73333333
76.8
74.66666667
68.8
74.4
72.26666667
73.6
74.66666667
78.4
78.4
73.6
72.53333333
76.8
74.13333333
75.2
73.6
74.66666667
73.86666667
80
77.33333333
72.53333333
Duration 
Group-
Dex
Group-
Midaz
Duration 47.8 45.97
Sd 6.13 4.04
t-Value
Df
p-value
Intubation 
Group-
Dex
Group-
Midaz
Intubation 
Mean
17.87 19.23
Sd 3.45 4.09
1.37
58
0.18 (Not Significant )
20
Intubation Mean
Duration
44
46
48
Duration
Intubation Mean
t-Value
Df
p-value
BI Sedation Scale
Group-
Dex
Group-
Midaz
BI Sedation Sca 2.00 2
Sd 0.59 0.35
t-Value
Df
p-value
-1.42
58
0.16 ( insignificant )
1.07
58
0.29 (Not Significant )
Intubation …17
18
19
Intub
1.90
1.92
1.94
1.96
1.98
2.00
BI Sedation Scale Me
Intubation …17
18
19
20
In
AE Sedation Scale
Group-
Dex
Group-
Midaz
AE Sedation Sca 2.4 2.8
Sd 0.62 0.41
t-Value
Df
p-value 0.01
2.95
58
Group-
Dex
Group-
Midaz
VAS 2.4 2.8
Sd 0.62 0.41
t-Value
Df
p-value
MAP
Preop BI BIN 1 min 2 min 3 min 15 min
DEX 94 84 94 94 92 88 80
MID 91 86 92 104 100 95 100
2.95
58
0.01
O2 SATURATION
Preop 10min 20min 30min 40min 50min 1hr
DEX 99 99 99 99 98 98 98
MID 99 99 99 97 96 97 97
VAS
DEX 3.87 2.07 1.33
MID 4.40 1.43 1.67
Side Effects 3
3.5
4
4.5
5
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
VAS
GROUP -
D GROUP - M
Bradycardia 5 0
Hypotension 0 1
Shivering 0 2
Nausea 2 2
Vomiting 2 0
Table-1
Sex distribution of the Sample 
N % N % N %
Male 14 46.7 19 63.3 33 55
Female 16 53.3 11 36.7 27 45
N=30
Group-Midaz
N=30
Group-Dex
Sex
Total
N=60
0
0.5
1
1.5
2
2.5
Br
ad
yc
ar
di
a
H
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ot
en
si
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g
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au
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a
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m
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Chi-square 
value
Df
p value
Table-2
Age Distribution of the Study Sample 
MALE FEMALE MALE FEMALE MALE FEMALE
 ≤ 20 6 4 6 2 12 6
21-30 6 11 12 7 18 18
31-40 2 7 1 2 3 9
Mean (sd)
T-value
Df
p-value 
0.54
58
0.60 (Not Significant)
Group-Dex Group-Midaz Total
23.40 (4.58) 24.03 (4.59) 23.72 (4.56)
0.19 (Not Significant )
1.68
1
Weight
Group-
Dex
Group-
Midaz
Mean 58.03 58.03
Sd 5.58 5.58
t-Value
Df
p-value
Height 
Group-
Dex
Group-
Midaz
1.000 (Not Significant)
58
0
Mean 158.43 158.43
Sd 5.01 5.01
t-Value
Df
p-value
ASA_Status
N % N %
I 26 86.7 27 90
II 4 13.3 3 10
Total 30 100 30 100
Chi square 
Value *
Df
Significant
0.16
1
0.69 (Not Significant )
Group-Dex
1.000 (Not Significant 
)
58
0
Group-Midaz
Duration 
Group-
Dex
Group-
Midaz
Mean 47.8 45.97
Sd 6.13 4.04
t-Value
Df
p-value
Intubation 
Group-
Dex
Group-
Midaz
Mean 17 87 34 83
1.37
58
0.18 (Not Significant )
. .
Sd 3.45 5.94
t-Value
Df
p-value
Pulse Rate 
Group 
–Dex
Group-
Midaz p-Value
Mean ± sd Mean ± sd df=58
Pre OP 83.70 ± 8.59
82.50 ± 
7.58 0.57 0.57 *
Intra OP 60.97 ± 6.57
69.10 ± 
7.42 4.45 0.0001
Bin 65.57 ± 6.48
 74.53 ± 
8.81 4.49 0.0001
Mint 1 75.57 ±  6.47
100.80 ± 
8.66 12.33 0.0001
Mint 2   77.17 ± 12.36
  95.13 ± 
9.26 6.37 0.0001
Mint 3 67.53 ± 6.36
73.93 ± 
7.30 3.62 0.001
13.52
58
0.0001 ( Significant )
Pulse Rate at t-value
Mint 15 81.23 ± 8.39
80.23 ± 
6.65 0.511 0.61*
Mint 30 67.27 ± 9.40
79.07 ± 
6.54 5.65 0.0001
Hour 1 78.77 ± 9.47
82.60 ± 
8.01 1.69 0.096*
Hour 2 74.10 ± 7.07
76.57 ± 
6.32 1.43 0.160*
Hour 4 76.93 ± 10.35
 82.37 ± 
11.28 1.95 0.057*
Hour 6 78.77 ± 8.74
81.70 ± 
8.45 1.32 0.19*
Hour 8 81.03 ± 11.53
83.90 ± 
10.40 1.01 0.32*
Hour 10 82.27 ± 9.21
85.77 ± 
10.65 1.36 0.18*
* - Not Significant 
Systolic Blood Pressure 
 
Group Group 
–Dex
-
Midaz p-Value
Mean ± sd Mean ± sd df=58
Pre OP 120.93 ± 11.05
121.00 ± 
5.55 0.03 0.98 *
Intra OP 113.37 ± 8.95
118.13 ± 
5.75 2.46 0.017
Bin 113.43 ± 5.37
113.43 ± 
5.37 0 1.000*
Mint 1 136.17 ± 9.29
143.37 ± 
6.18 3.53 0.001
Mint 2   121.83 ±12.66
120.90 ± 
13.93 0.27 0.79*
Mint 3 109.77 ± 7.10
110.63 ± 
6.95 0.48 0.63*
Mint 15 128.10 ± 16.75
134.60 ± 
9.30 1.86 0.07*
Mint 30 118.73 ± 15.94
127.87 ± 
15.40 2.56 0.03
Mint 45 129.10 ±18.19
131.40 ± 
15.53 0.53 0.60*
Hour 1 105.67 ± 7.95
105.67 ± 
7.95 0 1.00*
Hour 2 107.57 ± 6.73
107.57 ± 
6.73 0 1.00*
Blood 
Pressure at t-value
Hour 4 108.47 ± 6.73
 108.47 ± 
6.73 0 1.00*
Hour 6 109.30 ± 6.24
109.30 ± 
6.24 0 1.00*
Hour 8 107.53 ± 6.12
107.53 ± 
6.12 0 1.00*
Hour 10 109.57 ± 4.93
109.57 ± 
4.93 0 1.00*
* - Not Significant 
Diastolic Blood Pressure 
Group 
–Dex
Group-
Midaz p-Value
Mean ± sd Mean ± sd df=58
Pre OP 80.70 ± 4.36
80.70 ± 
4.36 0 1.000*
Intra OP 69.47 ± 6.48
69.47 ± 
6.48 0 1.000*
Bin 84.20 ± 7 68
84.20 ± 
7 68 0 1.000*
Blood 
Pressure at t-value
. .
Mint 1 85.70 ± 7.53
85.70 ± 
7.53 0 1.000*
Mint 2 90.10 ± 7.33
90.10 ± 
7.33 0 1.000*
Mint 3 76.87 ±11.34
87.33 ± 
11.67 3.52 0.001
Mint 15 61.13 ± 11.71
82.03 ± 
8.24 7.99 0.0001
Mint 30 66.10 ± 8.87
85.60 ± 
6.25 9.84 0.0001
Mint 45 83.03 ± 7.65
84.63 ± 
6.37 0.88 0.382*
Hour 1 76.17 ± 9.66
76.17 ± 
9.66 0 1.000*
Hour 2 72.87 ± 4.60
72.87 ± 
4.60 0 1.000*
Hour 4 70.07 ± 6.28
 73.67 ± 
3.02 2.83 0.01
Hour 6 70.20 ± 6.29
73.03 ± 
4.55 1.99 0.05
Hour 8 69.57 ± 7.88
74.93 ± 
3.44 3.42 0.001
Hour 10 68.30 ± 6.55
75.67 ± 
2.62 5.72 0.0001
* - Not Significant 
BI Sedation Scale
sedation
Group-
Dex
Group-
Midaz
Group-
Dex
Group-
Midaz
Mean 2 1.87 BI 2 1.87
Sd 0.59 0.35 AE 2.4 2.8
t-Value
Df
p-value
AE Sedation Scale
Group-
Dex
Group-
Midaz
Mean 2.4 2.8
1.07
58
0.29 (Not Significant )
1
1.5
2
2.5
3
BI
AE
Sd 0.62 0.41
t-Value
Df
p-value
Graph-1
Pulse Rate 
Pulse Rate at Group –DexGroup-Midaz
Pre OP 83.7 82.5
Intra OP 60.97 69.1
Bin 65.57 74.53
Mint 1 75.57 100.8
Mint 2 77.17 95.13
Mint 3 67.53 73.93
Mint 15 81.23 80.23
Mint 30 67.27 79.07
Hour 1 78.77 82.6
Hour 2 74.1 76.57
Hour 4 76.93 82.37
Hour 6 78.77 81.7
Hour 8 81.03 83.9
0.01
2.95
58
0
0.5
Group‐Dex Group‐Midaz
Hour 10 82.27 85.77
Graph-2
Systolic Blood Pressure 
 
Group 
–Dex
Group-
Midaz
Pre OP 120.93 121.00
Intra OP 113.37 118.13
Bin 113.43 113.43
Mint 1 136.17 143.37
Mint 2 121.83 120.90
Mint 3 109.77 110.63
Mint 15 128.10 134.60
Mint 30 118.73 127.87
Mint 45 129.10 131.40
Hour 1 105.67 105.67
Hour 2 107.57 107.57
Hour 4 108.47 108.47
Hour 6 109.30 109.30
Hour 8 107.53 107.53
Hour 10 109.57 109.57
Graph-3
Diastolic Blood Pressure 
Group 
–Dex Group-Midaz
Pre OP 80.7 80.7
Intra OP 69.47 69.47
Bin 84.2 84.2
Mint 1 85.7 85.7
Mint 2 90.1 90.1
Mint 3 76.87 87.33
Mint 15 61.13 82.03
Mint 30 66.1 85.6
Mint 45 83.03 84.63
Hour 1 76.17 76.17
Hour 2 72.87 72.87
Hour 4 70.07 73.67
Hour 6 70.2 73.03
Hour 8 69.57 74.93
Hour 10 68.3 75.67
Graph-4
Male Female
Group-Dex 14 16
Group-Midaz 19 11
Graph-5
Age Group Group-Dex Group-Midaz
 ≤ 20 10 8
21-30 17 19
31-40 3 3
Graph-6
ASA Status
I II
Group-Dex 26 4
Group-Midaz 27 3
40
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Dex 94 84 94 103 101 88 83
MAP Preop BI BIN 1 min 2 min 3 min 15 min
MID 94 86 94 105 100 95 100
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Side Effects 
GROUP ‐ D
Side Effects 
GROUP ‐ M
MID
84 83 83 82 82
2 HR 4 HR 6 HR 8 HR 10 HR
84 85 85 86 87
2
DEX
DEX
MID
3 
m
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15
 m
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2 
H
R
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H
R
6 
H
R
8 
H
R
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 H
R
MAP
MID
Sl. No order date Name Age Sex Wt Diagnosis
1 19.6.12 Kalyani 28 F 50 sub acute appendicitis
2 20.6.12 prakash 19 M 48 sub acute appendicitis
3 21.6.12 yasodha 23 F 54 sub acute appendicitis
4 21.6.12 praveen 24 M 58 sub acute appendicitis
5 22.6.12 mohan 18 M 49 sub acute appendicitis
6 23.6.12 nasreen begam 22 F 60 sub acute appendicitis
7 25.6.12 Kalyani 16 M 51 sub acute appendicitis
8 25.6.12 Sukumar 21 M 59 sub acute appendicitis
9 26.6.12 Selvi 20 F 54 sub acute appendicitis
10 28.6.12 Rathinam 30 M 63 sub acute appendicitis
11 29.6.12 Balambika 28 F 60 sub acute appendicitis
12 02.7.12 Martin 22 M 57 sub acute appendicitis
13 20.7.12 Devi sree 20 F 67 sub acute appendicitis
14 21.7.12 saminathan 30 M 58 sub acute appendicitis
15 21.7.12 Prabhu 19 M 49 sub acute appendicitis
16 23.7.12 Kumari 28 F 62 sub acute appendicitis
17 23.7.12 Bakiyaraj 17 M 48 sub acute appendicitis
18 24.7.12 Senthil 31 M 66 adhesive colic
19 26.7.12 Babu sundar 22 M 51 sub acute appendicitis
20 26.7.12 Venila 25 F 47 sub acute appendicitis
21 27.7.12 Satanathan 28 M 58 sub acute appendicitis
22 10.8.12 Saraswathi 31 F 64 sub acute appendicitis
23 10.8.12 Kanan 25 M 60 sub acute appendicitis
24 11.8.12 Senthil vijay 28 M 60 sub acute appendicitis
25 14.8.12 Vignesh 19 M 51 sub acute appendicitis
26 23.8.12 Meenakshi 27 F 55 sub acute appendicitis
27 23.8.12 Ganesh 22 M 59 sub acute appendicitis
28 24.8.12 Raja 24 M 62 sub acute appendicitis
29 25.8.12 Vadivu 32 F 65 adhesive colic
30 27.8.12 Arivoli 22 M 52 sub acute appendicitis
Mean 24.03 56.57
Stdev 4.59 5.92
MASTER CHART  GROUP- M (Midax)
SSS
Procedure ASA Status Duration BI PreOP BI Intubation Preop
Laproscopic Appendicectomy I 45 2 5 2 15 99
Laproscopic Appendicectomy I 50 2 3 1 15 100
Laproscopic Appendicectomy I 45 2 4 1 22 99
Laproscopic Appendicectomy I 40 2 5 1 23 99
Laproscopic Appendicectomy I 45 2 3 1 20 100
Laproscopic Appendicectomy II(old pt) 50 2 5 2 20 99
Laproscopic Appendicectomy I 45 2 3 3 22 99
Laproscopic Appendicectomy I 50 2 3 1 20 100
Laproscopic Appendicectomy I 50 2 5 1 25 100
Laproscopic Appendicectomy I 40 1 5 1 20 100
Laproscopic Appendicectomy I 45 2 4 1 25 99
Laproscopic Appendicectomy II(HT) 50 1 5 1 15 99
Laproscopic Appendicectomy I 45 2 3 2 15 99
Laproscopic Appendicectomy I 45 2 5 1 20 100
Laproscopic Appendicectomy I 50 2 5 1 25 99
Laproscopic Appendicectomy I 55 2 3 2 10 99
Laproscopic Appendicectomy I 45 2 5 2 10 99
 laproscopic  adhesiolysis I 50 2 3 1 15 99
Laproscopic Appendicectomy I 40 2 5 2 20 99
Laproscopic Appendicectomy I 40 2 4 2 20 99
Laproscopic Appendicectomy I 40 2 4 1 20 99
Laproscopic Appendicectomy I 44 2 5 1 25 99
Laproscopic Appendicectomy I 45 2 5 2 20 99
Laproscopic Appendicectomy I 50 2 5 1 18 99
Laproscopic Appendicectomy I 45 2 5 2 18 99
Laproscopic Appendicectomy I 45 2 5 1 16 99
Laproscopic Appendicectomy II(obese) 50 2 3 1 25 99
Laproscopic Appendicectomy I 50 2 6 1 22 99
 laproscopic  adhesiolysis I 40 2 6 2 18 99
Laproscopic Appendicectomy I 45 2 5 2 18 99
45.97 2 4.40 1.43 19.23 99
4.04 0.25 0.97 0.57 4.09 99
VAS
10min20min 20min30min 30 40min 50min ihr Preop BI BIN 1 min 2 min 3 min 15 min
100 99 98 98 95 97 66 55 55 93 87 61 65
99 99 98 95 96 97 84 70 76 101 96 74 76
99 98 95 95 96 98 74 62 62 94 88 65 68
99 98 97 98 96 98 79 66 72 100 95 78 78
100 99 98 99 95 98 74 60 70 84 79 74 76
99 99 99 98 96 98 66 55 58 97 96 62 66
99 98 98 98 97 96 98 83 96 100 102 86 88
99 98 99 95 98 96 94 80 90 96 90 82 88
98 98 98 98 96 96 82 70 80 110 105 80 88
99 99 96 95 98 96 84 71 80 120 116 84 82
99 99 96 95 95 98 60 68 76 117 94 78 90
100 99 99 98 95 98 61 66 66 109 94 64 78
99 98 99 95 99 96 84 71 65 97 91 60 80
99 98 94 95 96 96 88 74 83 99 95 72 80
98 98 94 96 98 95 78 63 76 102 90 72 82
100 99 93 95 96 96 76 62 74 98 82 70 72
99 98 99 96 97 98 92 78 80 99 98 84 86
99 98 95 96 95 96 84 71 82 92 90 76 78
100 99 94 96 98 97 72 59 70 96 90 72 78
99 99 98 98 99 97 80 68 82 112 109 78 84
99 98 94 95 96 96 90 74 71 86 78 73 74
99 99 98 96 96 98 85 66 81 92 91 77 86
100 99 94 95 96 96 89 69 83 99 98 82 82
99 99 99 97 98 96 82 71 71 93 90 71 83
98 98 95 98 97 98 80 80 68 97 88 80 83
99 99 96 96 97 98 91 81 69 102 106 83 86
99 98 97 96 98 98 80 77 76 112 108 72 81
99 99 98 98 98 95 83 62 71 109 103 64 91
99 99 99 97 96 98 90 68 79 110 112 69 78
100 99 98 96 97 98 88 73 74 108 93 75 79
99 99 97 96 97 97 81.13 69.10 74.53 100.80 95.13 73.93 80.20
99 99 97 96 97 97 9.42 7.42 8.81 8.66 9.26 7.30 6.66
Oxygen Saturation Pu
30min 45min 1hr 2hr 4hr 6hr 8hr 10hr Preop BIN 1min 2min 3min
68 69 88 68 88 76 101 104 128 120 116 132 122 110
78 72 90 86 86 86 86 90 116 112 110 140 124 108
70 75 88 76 94 82 84 86 124 122 120 155 129 120
76 72 82 70 82 84 88 86 130 124 116 145 132 112
72 74 78 80 80 80 82 82 128 126 120 137 101 122
78 75 80 70 84 82 84 86 110 108 106 135 98 106
78 68 90 86 99 96 100 103 124 124 122 140 129 120
78 77 88 82 82 85 90 88 126 124 120 150 99 120
90 79 84 64 80 84 84 82 112 108 104 142 105 100
86 73 78 68 74 78 76 78 124 116 114 132 142 112
86 79 80 72 78 80 80 78 126 120 116 155 98 116
80 81 98 73 94 95 96 98 120 114 106 142 125 100
78 69 64 83 62 66 62 66 128 118 114 147 134 112
76 79 84 87 84 85 88 84 120 116 112 138 109 108
89 82 78 77 72 72 72 74 114 108 104 140 130 100
79 76 80 70 72 72 74 72 122 118 112 150 99 102
77 74 96 80 92 94 92 106 130 122 116 151 135 118
73 72 80 68 84 83 84 82 116 108 104 149 128 100
66 69 68 72 70 66 68 68 120 118 116 147 135 114
89 79 82 73 82 84 84 82 110 108 104 140 128 106
80 84 88 74 72 70 84 90 119 124 112 143 125 113
76 75 77 80 98 95 99 87 116 119 114 141 134 112
76 75 73 80 98 91 93 89 120 124 114 150 109 112
100 90 71 75 98 93 73 95 120 119 116 140 130 100
83 82 92 75 63 74 73 96 120 120 120 147 128 109
81 82 92 79 63 74 76 106 119 114 121 139 99 108
90 88 83 79 74 73 66 80 124 122 112 138 134 120
91 76 79 84 74 81 90 75 126 124 113 146 131 120
74 74 76 86 94 84 100 77 118 124 113 150 125 107
108 78 91 80 98 86 88 83 120 120 116 140 110 112
80.87 76.60 82.60 76.57 82.37 81.70 83.90 85.77 121.00 118.13 113.43
9.12 5.42 8.01 6.32 11.28 8.45 10.40 10.65 5.55 5.75
lse rate
15min30min 30min 45min 1hr 2hr 4hr 6hr 8hr 10hr Preop BI BIN
125 126 116 124 118 112 116 114 114 75 72 94
135 135 126 104 110 108 106 106 108 79 70 86
112 115 100 112 108 106 112 108 108 86 68 92
125 129 118 108 120 116 116 114 120 72 64 82
142 140 130 114 116 110 118 120 116 88 82 82
135 134 125 100 98 100 102 104 104 82 78 84
146 140 126 108 112 118 116 114 118 81 77 96
118 120 135 118 116 122 118 118 116 77 74 90
135 102 140 98 100 102 102 102 104 71 76 80
134 118 144 114 110 108 112 116 110 68 65 80
142 130 124 94 106 110 108 106 108 62 69 86
148 128 115 98 100 102 102 104 104 65 69 96
139 129 148 110 112 108 112 110 108 63 63 65
129 119 144 100 98 102 106 106 108 70 75 62
138 135 160 96 98 100 98 100 100 66 61 63
129 124 136 110 108 114 110 110 112 70 63 66
119 110 98 112 110 114 116 108 110 73 58 74
137 110 120 102 100 100 98 98 104 78 54 71
148 119 150 104 102 108 104 102 110 74 66 70
142 120 133 92 108 104 110 108 108 76 64 70
148 140 145 104 102 102 114 102 109 80 77 96
135 135 145 110 114 102 116 114 115 83 76 90
137 128 140 118 110 108 99 100 115 83 66 86
129 180 129 100 96 106 110 100 104 74 66 76
145 130 144 100 109 100 110 109 106 80 69 90
128 122 138 96 112 120 108 105 112 80 69 90
140 110 99 107 110 115 103 97 115 84 69 83
142 140 127 114 100 122 106 106 108 82 76 76
127 130 148 98 108 110 114 110 103 77 73 81
129 140 139 105 116 105 117 115 110 80 75 88
134.60 127.93 131.40 105.67 107.57 108.47 109.30 107.53 109.57 75.97 69.47 81.50
9.30 14.24 15.53 7.95 6.72 6.72 6.24 6.12 4.92 6.86 6.48 10.22
 
Systolic Blood Pressure
1 min 2 min 3 min 15 min 30min 45 min 1 HR 2 HR 4 HR 6 HR 8 HR 10 HR Preop BI
93 92 100 98 90 88 92 76 70 76 78 80 93 88
84 88 86 94 86 84 94 82 78 74 72 78 91 84
94 92 100 78 88 86 90 68 72 80 76 74 99 86
80 83 85 74 92 88 88 84 78 80 74 78 91 84
84 86 80 95 94 92 78 74 72 76 82 74 101 97
87 90 78 74 79 90 78 64 72 76 72 76 91 88
100 102 96 88 74 94 88 80 76 72 76 80 95 93
86 84 92 84 88 88 87 70 76 74 78 74 93 91
83 88 80 85 92 78 68 74 76 72 76 74 85 87
66 92 88 68 90 88 67 68 70 72 74 78 87 82
71 94 88 100 96 87 73 74 78 72 74 78 83 86
92 94 92 76 94 85 75 74 70 74 72 76 83 84
68 70 56 86 75 76 66 72 78 80 82 78 85 81
60 84 96 90 78 96 65 68 74 78 74 76 87 89
87 90 76 98 82 69 62 68 74 64 74 76 82 77
80 82 86 75 88 79 76 74 70 74 72 70 87 81
87 98 104 74 84 78 75 76 78 80 76 80 92 79
86 90 82 68 86 85 82 74 72 68 66 74 91 72
74 78 70 84 82 80 78 68 72 68 70 74 89 83
85 88 84 75 85 82 66 68 70 72 74 72 87 79
92 103 96 88 74 88 88 70 76 72 78 78 93 93
83 88 92 80 88 86 87 70 76 72 79 72 94 90
100 84 99 76 80 79 68 72 72 70 74 75 95 85
80 102 100 88 102 85 67 68 70 74 74 75 89 84
87 100 63 86 92 96 82 74 70 71 74 72 93 86
83 98 73 83 94 93 66 74 76 70 72 74 93 84
87 94 88 80 80 79 64 80 76 70 76 74 97 87
69 88 92 76 86 83 76 74 72 80 81 78 97 92
95 88 96 76 88 78 66 74 76 64 74 78 91 90
84 93 102 88 102 79 73 74 70 66 74 74 93 90
83.57 90.10 87.33 82.83 86.97 84.63 76.17 72.87 73.67 73.03 74.93 75.67 90.98 85.69
9.63 7.33 11.67 8.78 7.35 6.37 9.66 4.60 3.02 4.55 3.44 2.62 4.78 5.23
Diastolic Blood Pressure
BIN 1 min 2 min 3 min 15 min 30min 45 min 1 HR 2 HR 4 HR 6 HR 8 HR 10 HR ANALGESIA
101 106 102 103 107 102 97 103 90 84 89 90 91
94 103 100 93 108 102 98 97 91 88 85 83 88
101 114 104 107 89 97 91 97 81 83 91 87 85
93 102 99 94 91 104 98 95 96 91 92 87 92
95 102 91 94 111 109 105 90 88 85 90 95 88
91 103 93 87 94 97 102 85 75 81 85 83 85
105 113 111 104 107 96 105 95 91 90 87 89 93
100 107 89 101 95 99 104 97 85 91 89 91 88
88 103 94 87 102 95 99 78 83 85 82 85 84
91 88 109 96 90 99 107 83 82 83 85 88 89
96 99 95 97 114 107 99 80 85 89 84 85 88
99 109 104 95 100 105 95 83 83 81 83 83 85
81 94 91 75 104 93 100 81 85 88 91 91 88
79 86 92 100 103 92 112 77 78 83 87 85 87
77 105 103 84 111 100 99 73 78 83 75 83 84
81 103 88 91 93 100 98 87 85 85 86 85 84
88 108 110 109 89 93 85 87 87 90 92 87 90
82 107 103 88 91 94 97 89 83 81 78 77 84
85 98 97 85 105 94 103 87 79 84 80 81 86
81 103 101 91 97 97 99 75 81 81 85 85 84
101 109 110 102 108 96 107 93 81 85 86 86 88
98 102 103 99 98 104 106 95 85 85 87 91 86
95 117 92 103 96 96 99 85 85 84 80 83 88
89 100 111 100 102 128 100 78 77 82 86 83 85 30 mic FENT
100 107 109 78 106 105 112 88 86 80 84 86 83
100 102 98 85 98 103 108 76 87 91 83 83 87
93 104 107 99 100 90 86 78 90 89 81 83 88
88 95 102 101 98 104 98 89 83 89 89 89 88
92 113 100 100 93 102 101 77 85 87 81 86 86
97 103 99 105 102 115 99 84 88 82 83 88 86
92.14 103.50 100.37 95 100 101 100 86 84 85 85 86 87
7.72 6.93 7.02 114
MAP
Hypotension
Side effects Treatment
SHIVERING 74.13333333
73.06666667
78.93333333
Nausea 73.06666667
81.06666667
73.06666667
SHIVERING 76.26666667
74.66666667
67.73333333
69.33333333
66.66666667
66.66666667
67.73333333
69.33333333
Nausea 65.6
69.86666667
73.6
72.53333333
71.46666667
69.86666667
74.4
75.2
76.26666667
71.46666667
74.66666667
74.4
Nausea 77.86666667
77.33333333
72.53333333
74.66666667
72.78222222
3.821573499
0
